CN101316579A - Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions - Google Patents
Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions Download PDFInfo
- Publication number
- CN101316579A CN101316579A CNA2006800392162A CN200680039216A CN101316579A CN 101316579 A CN101316579 A CN 101316579A CN A2006800392162 A CNA2006800392162 A CN A2006800392162A CN 200680039216 A CN200680039216 A CN 200680039216A CN 101316579 A CN101316579 A CN 101316579A
- Authority
- CN
- China
- Prior art keywords
- film
- agent
- vitamin
- multivitamin
- antiplastering aid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 118
- 239000002552 dosage form Substances 0.000 title description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 156
- 238000000034 method Methods 0.000 claims abstract description 67
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 23
- 229940088594 vitamin Drugs 0.000 claims abstract description 17
- 229930003231 vitamin Natural products 0.000 claims abstract description 17
- 235000013343 vitamin Nutrition 0.000 claims abstract description 17
- 239000011782 vitamin Substances 0.000 claims abstract description 17
- -1 poly(ethylene oxide) Polymers 0.000 claims description 91
- 239000003814 drug Substances 0.000 claims description 89
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 83
- 238000001035 drying Methods 0.000 claims description 79
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 72
- 229920000642 polymer Polymers 0.000 claims description 59
- 239000000377 silicon dioxide Substances 0.000 claims description 39
- 235000012239 silicon dioxide Nutrition 0.000 claims description 38
- 238000000576 coating method Methods 0.000 claims description 36
- 235000019359 magnesium stearate Nutrition 0.000 claims description 36
- 239000011248 coating agent Substances 0.000 claims description 33
- 210000000214 mouth Anatomy 0.000 claims description 24
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 22
- 239000000758 substrate Substances 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 17
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 16
- 239000013543 active substance Substances 0.000 claims description 15
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 14
- 210000003298 dental enamel Anatomy 0.000 claims description 14
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 14
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 13
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 12
- 239000000314 lubricant Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 4
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 3
- 229960001985 dextromethorphan Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 9
- 239000002537 cosmetic Substances 0.000 abstract description 8
- 239000012867 bioactive agent Substances 0.000 abstract description 2
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000010408 film Substances 0.000 description 400
- 239000013589 supplement Substances 0.000 description 84
- 230000003213 activating effect Effects 0.000 description 62
- 239000000463 material Substances 0.000 description 47
- 239000002253 acid Substances 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- 239000000796 flavoring agent Substances 0.000 description 32
- 235000013355 food flavoring agent Nutrition 0.000 description 32
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 30
- 229960003987 melatonin Drugs 0.000 description 30
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 29
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 25
- 239000008187 granular material Substances 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 239000002245 particle Substances 0.000 description 23
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 19
- 239000012530 fluid Substances 0.000 description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- 239000002585 base Substances 0.000 description 14
- 229920001577 copolymer Polymers 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 239000004376 Sucralose Substances 0.000 description 13
- 238000012856 packing Methods 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 235000019408 sucralose Nutrition 0.000 description 13
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 13
- 239000004594 Masterbatch (MB) Substances 0.000 description 12
- 206010031009 Oral pain Diseases 0.000 description 12
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 12
- 239000010409 thin film Substances 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 239000003086 colorant Substances 0.000 description 11
- 239000000975 dye Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 206010011224 Cough Diseases 0.000 description 10
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 10
- 229930003427 Vitamin E Natural products 0.000 description 10
- 239000000654 additive Substances 0.000 description 10
- 239000002518 antifoaming agent Substances 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 238000013270 controlled release Methods 0.000 description 10
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 10
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical class CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 10
- 239000004014 plasticizer Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 229940083037 simethicone Drugs 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 10
- 235000019165 vitamin E Nutrition 0.000 description 10
- 239000011709 vitamin E Substances 0.000 description 10
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 9
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 241000282485 Vulpes vulpes Species 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 9
- 229940046009 vitamin E Drugs 0.000 description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 230000002776 aggregation Effects 0.000 description 8
- 229940062972 benzocaine / menthol Drugs 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- KYIRIOFLDIUOHN-UHFFFAOYSA-N ethyl 4-aminobenzoate;5-methyl-2-propan-2-ylcyclohexan-1-ol Chemical compound CC(C)C1CCC(C)CC1O.CCOC(=O)C1=CC=C(N)C=C1 KYIRIOFLDIUOHN-UHFFFAOYSA-N 0.000 description 8
- 235000011194 food seasoning agent Nutrition 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 239000002798 polar solvent Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 238000005266 casting Methods 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000004155 Chlorine dioxide Substances 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 235000019398 chlorine dioxide Nutrition 0.000 description 6
- 235000015165 citric acid Nutrition 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 6
- 150000005846 sugar alcohols Polymers 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 235000010489 acacia gum Nutrition 0.000 description 5
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 5
- 206010022000 influenza Diseases 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 235000010987 pectin Nutrition 0.000 description 5
- 239000001814 pectin Substances 0.000 description 5
- 229920001277 pectin Polymers 0.000 description 5
- 229920000747 poly(lactic acid) Polymers 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 5
- 239000004299 sodium benzoate Substances 0.000 description 5
- 235000010234 sodium benzoate Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004408 titanium dioxide Substances 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930003779 Vitamin B12 Natural products 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 238000007605 air drying Methods 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 229940069428 antacid Drugs 0.000 description 4
- 239000003159 antacid agent Substances 0.000 description 4
- 230000001458 anti-acid effect Effects 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000020971 citrus fruits Nutrition 0.000 description 4
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 229940041616 menthol Drugs 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000004302 potassium sorbate Substances 0.000 description 4
- 235000010241 potassium sorbate Nutrition 0.000 description 4
- 229940069338 potassium sorbate Drugs 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 235000013599 spices Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 235000019163 vitamin B12 Nutrition 0.000 description 4
- 239000011715 vitamin B12 Substances 0.000 description 4
- 235000019158 vitamin B6 Nutrition 0.000 description 4
- 239000011726 vitamin B6 Substances 0.000 description 4
- 229940011671 vitamin b6 Drugs 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 3
- 206010006326 Breath odour Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 3
- 235000007716 Citrus aurantium Nutrition 0.000 description 3
- 240000003791 Citrus myrtifolia Species 0.000 description 3
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 3
- 235000016646 Citrus taiwanica Nutrition 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- 239000004606 Fillers/Extenders Substances 0.000 description 3
- 229920002148 Gellan gum Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 208000032139 Halitosis Diseases 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000009470 Theobroma cacao Nutrition 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 229930003537 Vitamin B3 Natural products 0.000 description 3
- 235000009392 Vitis Nutrition 0.000 description 3
- 241000219095 Vitis Species 0.000 description 3
- 235000010358 acesulfame potassium Nutrition 0.000 description 3
- 229960004998 acesulfame potassium Drugs 0.000 description 3
- 239000000619 acesulfame-K Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 229920013820 alkyl cellulose Polymers 0.000 description 3
- HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940034982 antineoplastic agent Drugs 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 238000005452 bending Methods 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 125000004181 carboxyalkyl group Chemical group 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 3
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000000850 decongestant Substances 0.000 description 3
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 235000010492 gellan gum Nutrition 0.000 description 3
- 239000000216 gellan gum Substances 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 229960001438 immunostimulant agent Drugs 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000007763 reverse roll coating Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 235000019160 vitamin B3 Nutrition 0.000 description 3
- 239000011708 vitamin B3 Substances 0.000 description 3
- 229960000317 yohimbine Drugs 0.000 description 3
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 241000206575 Chondrus crispus Species 0.000 description 2
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 229920000305 Nylon 6,10 Polymers 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- SMTZFNFIKUPEJC-UHFFFAOYSA-N Roxane Chemical compound CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 SMTZFNFIKUPEJC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003571 Vitamin B5 Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229960003558 almasilate Drugs 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- JIFPTBLGXRKRAO-UHFFFAOYSA-K aluminum;magnesium;hydroxide;sulfate Chemical compound [OH-].[Mg+2].[Al+3].[O-]S([O-])(=O)=O JIFPTBLGXRKRAO-UHFFFAOYSA-K 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 229940125713 antianxiety drug Drugs 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940043671 antithyroid preparations Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 229960004754 astemizole Drugs 0.000 description 2
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 239000008376 breath freshener Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229960003563 calcium carbonate Drugs 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 229960001714 calcium phosphate Drugs 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910001919 chlorite Inorganic materials 0.000 description 2
- 229910052619 chlorite group Inorganic materials 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- WTEVQBCEXWBHNA-YFHOEESVSA-N citral B Natural products CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 2
- ZGRKFKYTCMLCCF-UHFFFAOYSA-N cobalt;oxalonitrile Chemical compound [Co].N#CC#N ZGRKFKYTCMLCCF-UHFFFAOYSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000007046 ethoxylation reaction Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229920006158 high molecular weight polymer Polymers 0.000 description 2
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 239000001023 inorganic pigment Substances 0.000 description 2
- 238000009685 knife-over-roll coating Methods 0.000 description 2
- 229940127021 low-dose drug Drugs 0.000 description 2
- 229960004018 magaldrate Drugs 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- 235000012254 magnesium hydroxide Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000246 remedial effect Effects 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 229960003320 roxatidine Drugs 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 230000014860 sensory perception of taste Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 2
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000009492 vitamin B5 Nutrition 0.000 description 2
- 239000011675 vitamin B5 Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011670 zinc gluconate Substances 0.000 description 2
- 235000011478 zinc gluconate Nutrition 0.000 description 2
- 229960000306 zinc gluconate Drugs 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- GHBDJTAKZXGXIP-GFCCVEGCSA-N (2r)-2-amino-2-benzylpentanedioic acid Chemical compound OC(=O)CC[C@](N)(C(O)=O)CC1=CC=CC=C1 GHBDJTAKZXGXIP-GFCCVEGCSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- BCVZNCWCAQBFPQ-UHFFFAOYSA-N 1,4-diethoxy-1,4-dioxobutane-2-sulfonic acid;sodium Chemical compound [Na].CCOC(=O)CC(S(O)(=O)=O)C(=O)OCC BCVZNCWCAQBFPQ-UHFFFAOYSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- ZKWASVBZSAGDBI-UHFFFAOYSA-N 2,6-dimethyloctan-1-ol Chemical compound CCC(C)CCCC(C)CO ZKWASVBZSAGDBI-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- NOHUXXDTQJPXSB-UHFFFAOYSA-N 2-acetyloxybenzoic acid;2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 NOHUXXDTQJPXSB-UHFFFAOYSA-N 0.000 description 1
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000019499 Citrus oil Nutrition 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 240000004530 Echinacea purpurea Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 229920003149 Eudragit® E 100 Polymers 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 244000286663 Ficus elastica Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 239000004348 Glyceryl diacetate Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 241000222065 Lycoperdon Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- AIDPNFMZHFRCCD-UHFFFAOYSA-K P(=O)([O-])([O-])[O-].[Ca+2].[Ca+2].[Al+3] Chemical compound P(=O)([O-])([O-])[O-].[Ca+2].[Ca+2].[Al+3] AIDPNFMZHFRCCD-UHFFFAOYSA-K 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000768494 Polymorphum Species 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000219 Sympatholytic Substances 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 description 1
- GRDYAIDYPXFQQV-UHFFFAOYSA-L [Al+3].O.O.O.O.O.O.O.S(=O)(=O)([O-])[O-].[Mg+2] Chemical compound [Al+3].O.O.O.O.O.O.O.S(=O)(=O)([O-])[O-].[Mg+2] GRDYAIDYPXFQQV-UHFFFAOYSA-L 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 229940003558 aggrenox Drugs 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003555 analeptic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003561 anti-manic effect Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000003208 anti-thyroid effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 239000002579 antinauseant Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- YNKMHABLMGIIFX-UHFFFAOYSA-N benzaldehyde;methane Chemical compound C.O=CC1=CC=CC=C1 YNKMHABLMGIIFX-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229940104825 bismuth aluminate Drugs 0.000 description 1
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 description 1
- 229940036358 bismuth subcarbonate Drugs 0.000 description 1
- JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 description 1
- 229960000199 bismuth subgallate Drugs 0.000 description 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940041750 cesamet Drugs 0.000 description 1
- SXPWTBGAZSPLHA-UHFFFAOYSA-M cetalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SXPWTBGAZSPLHA-UHFFFAOYSA-M 0.000 description 1
- 229960000228 cetalkonium chloride Drugs 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- JFBJUMZWZDHTIF-UHFFFAOYSA-N chlorine chlorite Inorganic materials ClOCl=O JFBJUMZWZDHTIF-UHFFFAOYSA-N 0.000 description 1
- 229960002688 choline salicylate Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 239000010500 citrus oil Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229940124978 clozopin Drugs 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 235000021210 cold soups Nutrition 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000007766 curtain coating Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000005137 deposition process Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- SAUMVKNLVQDHMJ-UHFFFAOYSA-N dichlorine trioxide Inorganic materials ClOCl(=O)=O SAUMVKNLVQDHMJ-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229950002377 ebrotidine Drugs 0.000 description 1
- ZQHFZHPUZXNPMF-UHFFFAOYSA-N ebrotidine Chemical compound S1C(N=C(N)N)=NC(CSCCN=CNS(=O)(=O)C=2C=CC(Br)=CC=2)=C1 ZQHFZHPUZXNPMF-UHFFFAOYSA-N 0.000 description 1
- 230000002196 ecbolic effect Effects 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 235000020694 echinacea extract Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- CEVCTNCUIVEQOY-STXHBLNNSA-N fumagillol Chemical compound C([C@@H](O)[C@H](C1[C@]2(C)[C@H](O2)CC=C(C)C)OC)C[C@@]21CO2 CEVCTNCUIVEQOY-STXHBLNNSA-N 0.000 description 1
- 238000007755 gap coating Methods 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- YBMRDBCBODYGJE-UHFFFAOYSA-N germanium oxide Inorganic materials O=[Ge]=O YBMRDBCBODYGJE-UHFFFAOYSA-N 0.000 description 1
- 235000019443 glyceryl diacetate Nutrition 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- PDSAKIXGSONUIX-UHFFFAOYSA-N hexaaluminum;dibismuth;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Bi+3].[Bi+3] PDSAKIXGSONUIX-UHFFFAOYSA-N 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940095970 imodium Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- LDHQCZJRKDOVOX-IHWYPQMZSA-N isocrotonic acid Chemical compound C\C=C/C(O)=O LDHQCZJRKDOVOX-IHWYPQMZSA-N 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 229940004916 magnesium glycinate Drugs 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- AACACXATQSKRQG-UHFFFAOYSA-L magnesium;2-aminoacetate Chemical compound [Mg+2].NCC([O-])=O.NCC([O-])=O AACACXATQSKRQG-UHFFFAOYSA-L 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- ZATZOOLBPDMARD-UHFFFAOYSA-N magnesium;hydrate Chemical compound O.[Mg] ZATZOOLBPDMARD-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 229950008866 mifentidine Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- GOZUADYOHPCXLE-UHFFFAOYSA-N n-[4-(1h-imidazol-5-yl)phenyl]-n'-propan-2-ylmethanimidamide Chemical compound C1=CC(NC=NC(C)C)=CC=C1C1=CN=CN1 GOZUADYOHPCXLE-UHFFFAOYSA-N 0.000 description 1
- 229960002967 nabilone Drugs 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229960003642 nicergoline Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229940105606 oxycontin Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 229960005183 paroxetine hydrochloride Drugs 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- QGWDKKHSDXWPET-UHFFFAOYSA-E pentabismuth;oxygen(2-);nonahydroxide;tetranitrate Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[O-2].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O QGWDKKHSDXWPET-UHFFFAOYSA-E 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229940094025 potassium bicarbonate Drugs 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000009342 ragweed pollen Substances 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229960003660 sertraline hydrochloride Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000000948 sympatholitic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008542 thermal sensitivity Effects 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- OXAGUGIXGVHDGD-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate;dihydrate Chemical compound O.O.[Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OXAGUGIXGVHDGD-UHFFFAOYSA-H 0.000 description 1
- VSJRDSLPNMGNFG-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate;trihydrate Chemical compound O.O.O.[Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O VSJRDSLPNMGNFG-UHFFFAOYSA-H 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960000881 verapamil hydrochloride Drugs 0.000 description 1
- 239000005419 vinegar essence Substances 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229920003170 water-soluble synthetic polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229940085658 zinc citrate trihydrate Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to water-soluble films incorporating anti-tacking agents and methods of their preparation. Anti-tacking agents may improve the flow characteristics of the compositions and thereby reduce the problem of film adhering to a user's mouth or to other units of film. In particular, the present invention relates to edible water-soluble delivery systems in the form of a film composition including a water-soluble polymer, an active component selected from cosmetic agents, pharmaceutical agents, vitamins, bioactive agents and combinations thereof and at least one anti-tacking agent.
Description
Invention field
The present invention relates to contain the rapidly dissolving film of antiplastering aid and their preparation method.Described film can also contain the active component that is evenly distributed in the film.
Related background art
Active component (as medicine or medicament) can be prepared into tablet form so that obtain accurate and uniform dosage.Yet the form of this preparation and distribution medicine has many shortcomings, comprising: must add a high proportion of adjuvant and just can reach manipulable dosage size, therefore bigger medicament forms needs extra storage area; And making up a prescription comprises when tablet counted and might bring inexactness.In addition, many people (estimation accounts for total population 28% more than) have any problem aspect swallow tablet.Although in order to overcome dysphagia, can make tablet rupture Cheng Gengxiao fragment or even it can be pulverized, for many tablets or pill form, this is not suitable solution.For example, pulverize or destroy tablet or pill form and absorb and also can destroy the sustained release characteristic so that mixes separately or with food.
As tablet and pill or the choosing, also can use film to carry active component, as medicine, medicament etc.Yet the film in past and have many unfavorable characteristics with this method for preparing drug delivery system can not adopt them in practice.
The United States Patent (USP) the 4th, 136, No. 145 (" Fuchs ") of expiration of time limit that is combined with people such as the film of active constituents of medicine such as Fuchs is described.These films can be made sheet, and drying cuts into each dosage then.The Fuchs open source literature has proposed to prepare the method for uniform films, comprises water-soluble polymer, surfactant, flavoring agent, sweeting agent, plasticizer and drug regimen.Disclosed that the softish film that these can be mentioned is used for oral, part or intestinal is used.The example of the concrete purposes that Fuchs discloses comprises the membranous part that film is used for health, comprises oral cavity, rectum, vagina, nose and ear.
Yet, according to the Fuchs disclosed method film is detected, find that particle aggregation or reunion can take place this class film, i.e. self aggregation, making them is uneven in essence.This possibility of result is that the method parameter by Fuchs causes, although not open, this method may comprise and adopts long drying time, reunites thereby impel intramolecularly captivation, convection current power, air-flow etc. to form this classes.
The formation of reuniting makes any activating agent of membrane component and existence be random distribution.When relating to heavy dose, the minor alteration of film size aspect all can cause the greatest differences of activating agent quantity in the every film.If comprise the low dosage activating agent in this class film, then some position of possible film is basically without any activating agent.Owing to diaphragm will be cut into unit dose usually, so some dosage may lack the activating agent of treatment suggestion or the quantity not sufficient of activating agent.It is deleterious to the patient that the cutting film can't obtain highly accurate active dose.For this reason, the dosage that forms as the processing method of Fuchs can not satisfy the strict standard of government or administrative organization such as the United States Federal's FAD (" FDA ") because the difference of active dose in its dosage form.At present, each worldwide administrative authority all requires the difference of the active dose that exists in the dosage form not surpass 10%.When being used for film base type, in fact be exactly to require to be present in the film equably.
Proposed to cause film uneven in the United States Patent (USP) of Schmidt the 4th, 849, No. 246 (" Schmidt ") from agglomeration traits.Schmidt spells out the Fuchs disclosed method can not provide uniform films, and recognizes that the generation of non-homogeneous film has hindered the accurate quantification that is even more important at pharmaceutical field as mentioned above.Schmidt has abandoned providing as monofilm as described in the Fuchs idea of accurate dosage form, replaces to attempt addressing this problem by forming multilayer film.And his method is the rapid process of the multistep of increase expense and complexity, does not have feasibility in the commerce utilization.
Other United States Patent (USP) has directly proposed the inherent granule of conventional film technique from reuniting and non-homogeneous problem.In once overcoming trial heterogeneous, the United States Patent (USP) 5,629 of Horstmann etc., 003 and the United States Patent (USP) 5,948,430 of Zerbe etc. in added other composition, promptly be respectively into gel and polyhydric alcohol, before dry, increase film viscosity to make great efforts to alleviate the gathering of component in the film.The shortcoming of these methods is to need other component, and this will change extra-pay and manufacturing step into.And these two kinds of methods have all been utilized conventional time-consuming drying means, bathe as the high temperature air that uses drying oven, drying tunnel, vacuum desiccator or other this class drying equipment.Although used viscous modifier, long-time drying still can impel activating agent and other adjuvant to assemble.This class course of processing is also being emitted and is being made activating agent (be medicine, or vitamin C, or other component) Long contact time moisture and high temperature and its was lost efficacy or even deleterious risk.
Activating agent can be degraded during worrying long-term contact wetting, itself can not provide uniform films the conventional drying method.Thermo-contact time span during the conventional processing is often referred to " heat history (heat history) ", carries out the heat treated mode of this class the formation and the form thereof of gained film product had a direct impact.The conventional drying method that is fit to very much the thicker relatively film of bound drug activating agent via needs especially is difficult to reach uniformity.Because when dry, the film surface does not experience identical external condition simultaneously with film inside, therefore the thicker uniform films of more difficult acquisition.Therefore, the observation of the thicker film that the conventional processing method of this class is made shows the heterogeneous texture that convection current and intramolecular force produce, and is higher than 10% moisture in order to keep flexible needs.Free water component interference medicament for a long time brings potential problems, thereby final products can not be kept consistently.
The conventional drying method generally includes the forced hot air that utilization is produced by drying oven, drying tunnel etc.The difficulty that obtains uniform films is directly relevant with the water evaporation process in the rheological equationm of state and the film-forming composition.When aqueous solutions of polymers surface contacted with high temperature gas flow, during by air stove, superficial water evaporated at once and forms polymeric film or skin from the teeth outwards as film-forming composition.Sealed surperficial following remaining aqueous film-forming composition like this, formed barrier one, remaining water must oneself be made great efforts to penetrate this road film and could be evaporated, to obtain exsiccant film.Along with the lasting rising of the outer temperature of film, the following water vapor pressure in film surface increases, and the stretched film surface is finally torn the film surface and made the water vapour loss.In case after the water vapour loss, described polymer film surface can form again, repeats this process, up to the film bone dry.Observe the result who constantly destroys and form again in the film surface and produce uneven and " chain reaction " of uneven film thus.Usually, according to different polymer, the surface makes remaining shipwreck to discharge deadend, causes very long drying time, higher temperature and power consumption more.
Other factors as hybrid technology, also plays effect in manufacturing is suitable for the pharmaceutical film of commercialization and management board approval.Air may be entrained in the compositions between mixing period or during the system film afterwards, when the drying stage water evaporates, may in the film product, reserve a little spaces like this.Near the described space film usually can destroy, and causes the film air spots smooth and cause telolemma product inhomogeneous thus.Even in the described film that bubble causes do not break in the space, uniformity still can be influenced.Because the space of described non-uniform Distribution is to be occupied the zone by what film composition occupied under other situation, so this situation also provides non-homogeneous film.None mentions above-mentioned patent or proposes to solve by the scheme that air threw into question that enters film.
And preceding in first packing (as medicinal cupping) and secondary package (as medicated bag or blister package), film will experience many procedure of processings earlier.Described procedure of processing is great challenge for the high-quality film that exploitation has best film surface characteristic such as low-friction coefficient or high sliding rate.The main points of whole process are at the integrity of keeping film during begin to be fabricated onto final packaging.Therefore, need prevent or alleviate the problem that diminishes film integrality that as after after a while, film softens, is clamminess, adheres to, becomes dry or becomes fragile.
Say that more specifically OTC (over-the-counter) film product as sugar-coat and respiratory membrane, is packaged in the medicinal cupping that contains 16 film units (also being called lath) or more a plurality of film unit (every jar reaches 24 or even 32 lamina membranacea bars).Every jar lamina membranacea bar quantity changes according to factors such as product type, active dose and packing configurations.Yet, when at a plurality of template bar of jar intermediate package, the inter-adhesive problem of lath usually can appear.
Adhesion is the problem that the edible film product usually can run between the lamina membranacea bar, may be caused by a variety of causes.For example, under the certain situation, adhesion may be to be caused by the component that adopts in the film manufacturing between the template bar.Component such as flavoring agent, plasticizer and activating agent sometimes can soften film and the quality of film is had adverse effect in the film.For example, in the film with high-load acidify agent, acid can produce extra plastication to film.The number acid in the film or the hygroscopicity of other component may be strengthened this class influence.
Under the certain situation, the adhesion between the lamina membranacea bar may be to change the film qualitative change that causes by temperature and/or humidity to cause.Some films can become sticky when non-optimum temperature of Long contact time and/or damp condition.This problem can be amplified in the very narrow product of best storage temperature and/or humidity range.
In general, show viscosity or may there be many problems in the film that can become sticky after a period of time.At first, when film has viscosity, will always roll up and change son volume into, and further change the lamina membranacea bar into and become more difficult in fact.In addition, when superposeing in packing as jar, the adhesive film lath can be bonded to each other.Therefore, user is difficult to once take out a lamina membranacea bar from the film packing.Generally speaking, this class adhesion in the packing has reduced the aesthetic property of lamina membranacea bar and the facility that individual consumer is used.
Therefore, the compositions that each film can be slided relative to one another, thereby provide be convenient to transform, storage stability is the highest and consumer is easy to benefits such as use.In addition, need the method for this class film of preparation, make component wherein keep uniform distribution, thereby prevent undesirable clustering phenomena and improve the uniformity of telolemma product.
Summary of the invention
One aspect of the present invention provides a kind of edible film that is used for active agent delivery, and described film comprises: the edible water-soluble polymer; At least a antiplastering aid that is selected from lubricant, antitack agent, fluidizer and combination thereof; With the active component that is selected from enamel, medicament, vitamin, bioactivator and combination thereof, described film can self-supporting.
The present invention provides a kind of edible film that is used for active agent delivery on the other hand, and described film comprises: the edible water-soluble polymers compositions that contains at least a polymer that is selected from hydroxypropyl cellulose, hydroxypropyl emthylcellulose, poly(ethylene oxide) and combination thereof; Be selected from the active component of enamel, medicament, vitamin, bioactivator and combination thereof; With contain the antiplastering aid that content accounts for the vitamin E TPGS of the heavy 0.01-20% of film.
The present invention provides a kind of edible film that is used for active agent delivery on the other hand, and described film comprises: contain poly(ethylene oxide) and the edible water-soluble polymers compositions that is selected from hydroxypropyl cellulose, hydroxypropyl emthylcellulose and combination of polymers thereof; Be enough to provide vitamin E TPGS anti-stick and the treatment characteristic with content, described film can self-supporting.
In some embodiments, a kind of edible film that is used for active agent delivery is provided, described film comprises: the edible water-soluble polymer that contains poly(ethylene oxide), hydroxypropyl cellulose and dextrosan, wherein, poly(ethylene oxide): hydroxypropyl cellulose: the ratio of dextrosan is about 45: 45: 10; Be selected from the active component of enamel, medicament, vitamin, bioactivator and combination thereof; With at least a antiplastering aid.
On the other hand, provide a kind of edible film that is used for active agent delivery, described film comprises: (a) have at least one surperficial self-supporting film, described film comprises: (i) edible water-soluble polymer; (ii) be selected from the active component of enamel, medicament, vitamin, bioactivator and combination thereof; (b) be positioned at least one lip-deep covering of self-supporting film, described covering contains at least a antiplastering aid.
Some embodiments provide a kind of multilayer film that is used for active agent delivery, and described film comprises: (a) at least one first rete, and it contains: (i) edible water-soluble polymer and (ii) antiplastering aid; (b) second rete, the active component that it contains (i) edible water-soluble polymer and (ii) is selected from enamel, medicament, vitamin, bioactivator and combination thereof.Described first rete contacts basically with described second rete.
The present invention also provides the method for preparing the equally distributed basically self-supporting film of each component, may further comprise the steps: with the edible water-soluble polymer, solvent, the active component and at least a antiplastering aid that are selected from enamel, medicament, vitamin, bioactivator and combination thereof are combined to form the equally distributed substrate of each component; Form the self-supporting film by substrate; Surface with end face and bottom surface is provided; Described film is transported to the end face on described surface; With by the heating of the bottom surface on described surface is made the film drying.
Brief Description Of Drawings
Fig. 1 shows the side view of the packing that contains unit dose film of the present invention.
Fig. 2 shows two top views in abutting connection with packing that contain independent unit dosage forms of the present invention, separates by tearing perforation.
Fig. 3 shows the side view of Fig. 2 of stacking construction arrangement in abutting connection with packing.
Fig. 4 shows the perspective view of the allotter that distributes described encapsulation unit dosage forms, and allotter contains the encapsulation unit dosage forms of stacking construction.
Fig. 5 is the sketch map of the paired unit dose packaging of a volume of the present invention.
Fig. 6 is the sketch map that is suitable for being pre-mixed, adding activating agent and follows the film forming manufacturing equipment of shape.
Fig. 7 is the sketch map that is suitable for the equipment of dry film of the present invention.
Detailed Description Of The Invention
For purposes of the present invention; term " non-self aggregation is evenly heterogeneous " refers to the performance of film of the present invention; described film adds that by one or more components polar solvent forms, and can significantly reduce the phenomenon that component is assembled or reunited in the film that usually can experience when (namely almost or fully not occuring) forms film with the conventional drying method such as high temperature air bath, drying tunnel, vacuum desiccator or other this class drying equipment that adopts drying oven. The term " heterogeneity " that the present invention adopts comprises in conjunction with one-component such as polymer, and the film of the combination of each component such as polymer and activating agent. " evenly heterogeneous " comprises gathering or the reunion that usually can occur when basically not adopting conventional mixing and heated drying method to form film.
And the thickness of film of the present invention is basically consistent, and this also is that conventional drying method for drying water based polyalcohol system can not provide. Can't obtain consistent thickness the uniformity that component distributes in given diaphragm area is produced adverse effect.
By polymer and the polar solvent of suitable selection, or select the combination that also comprises a kind of active component and other fillers as known in the art to produce film product of the present invention. By adopting selected casting or deposition process and controllable dry drying method, it is evenly heterogeneous that the component in these films has non-self aggregation. The example of controllable dry drying method includes but not limited to: the United States Patent (USP) the 4th that uses Magoon, 631, disclosed equipment in No. 837 (" Magoon ") (it is for referencial use to include in full this paper in it), and the hot-air impingement flow is through bottom and bottom-heated dish. The another kind of dry technology that obtains film of the present invention is not have the not controlled radiant drying of controlled airflow, such as infrared ray and radio-frequency radiation (being microwave).
The purpose of described drying means provides the membrane drying process of avoided purposely causing complication (such as famous " ripples " effect), and it is relevant with the conventional drying method, and at first then the upper surface of desciccator diaphragm collects internal moisture. In the conventional oven drying means, when the moisture of internal gathering evaporated subsequently, end face was torn and changes, and then again formed. The present invention has avoided these complicated processes, by the bottom surface of first desciccator diaphragm or avoided the film end face to form polymer film (skin) before the desciccator diaphragm depths providing uniform films. This can realize in the following manner: to film bottom surface heating and the top there is no air-flow; Perhaps adopt control microwave to come evaporating film interior moisture or other polar solvent, same, the top there is no air-flow. Also or choosing, can flow to realize drying by adopting balanced fluid, the airflow balancing of uniform films is provided such as control bottom and top stream. In this case, point to the situation that power that the described air-flow at film top should not can cause air-flow to produce moves the particle that exists in the wet film. In addition, the air-flow that points to the film bottom is preferably controlled, thereby makes the film can the lifting because of the power of air-flow. Not controlled airflow above or below the film can cause inhomogeneous in telolemma product. The humidity level that can also suitably regulate the end face peripheral region prevents the too early closure of polymer surfaces or skinning.
This membrane drying process has a plurality of advantages. Comprising drying time and more uniform film are surperficial faster, and each component evenly distributes in any given area of film. In addition, faster drying time can be in film very fast generation viscosity, further support each component evenly to distribute and reduce the gathering of each component in the telolemma product. Ideally, the drying of film is at about 10 minutes or shorter or betterly carry out in about 5 minutes or shorter time.
When paying close attention to the cohesion that reduces each component of composition, the present invention can produce especially uniformly film product. Introduce and dispose excess air by avoiding in mixed process, selective polymer and solvent provide controlled viscosity, and by upwards film being carried out drying from the bottom fast, can obtain this class film.
Product of the present invention and method rely on each production stage of described film to cooperatively interact to provide the film of each component self aggregation in the remarkable minimizing film. Particularly, these steps comprise concrete film build method, prevent from carrying secretly composition mixture preparation method, the viscosity that is controlled to film composition and the membrane drying process that air inlet is steeped. More specifically, in order to prevent surfactant precipitate, when described activating agent was insoluble to selected polar solvent, component of mixture viscosity is higher then to be particularly useful. Yet viscosity can not be too high and hinder or hinder selected casting method, and described method should comprise the reverse roll coating, and this is because it can provide the basically film of consistency of thickness.
Except film viscosity or film-forming components or substrate, the present invention needs also to consider that other factors just can reach required film uniformity.For example, obtained to prevent that solid (as drug particles) from sedimentary stable suspension taking place in non-colloid is used.A kind of method provided by the invention is to make grain density (ρ
p) and density of liquid phase (ρ
1) reach balance and increase the viscosity (μ) of liquid phase.With regard to isolating granule, as follows about the Stokes' law (Stokes law) of the final settling velocity (Vo) of rigid spheres in viscous fluid of certain radius (r):
V
o=(2gr
r)(ρ
p-ρ
1)/9μ。
Yet when granule density is high, local granule concentration will influence local viscosity and density.The viscosity of suspension is the majorant (strong function) of fractional solid volume, and granule-granule and granule-liquid phase mutual effect will further hinder settling velocity.
The Stokes analysis shows the adding third phase, as dispersive air or nitrogen, can promote the stability of suspension.In addition, the increase amounts of particles can produce the precipitation of being obstructed based on fractional solid volume.In the particle suspension liquid of dilution, settling rate, v can be expressed as:
Wherein κ is a constant,
It is the volume fraction of dispersive thing phase.The granule increase that is suspended in the liquid phase can cause speed to reduce.Because particle size can influence granule-particulate mobile mutual effect, so the particle geometric shape also is a key factor.
Similarly, the viscosity of suspension depends on the volume fraction of dispersing solid.With regard to the diluted suspension of the spheroidal particle of no mutual effect, the viscosity of suspension can be expressed as:
μ/μ
o=1+2.5φ
μ wherein
oBe the viscosity of continuous phase, φ is a fractional solid volume.When volume fraction was higher, the viscosity of dispersion can be expressed as:
Wherein C is a constant.
The viscosity of liquid phase is very crucial, and hope can be the viscoelasticity non-Newtonian fluid with low yield value of stress with the liquid improvement by the customization fluid composition.This and the static continuous phase equivalence of generation high viscosity.The fluid that forms viscoelasticity or highly structural is on good terms provides additional friction for solids precipitation.In addition, granule-granule is interacted drop to mental retardation control flocculation or assemble.Net effect is kept equally distributed thing phase exactly.
Aqueous phase toward suspension adds glue physical ability increase viscosity, can produce viscoelasticity and can give stability based on different hydrocolloid types, its concentration and particulate composition, geometry, size and volume fraction.Need by select in the high viscosity medium minimum actual grain size promptly<500mm, control the particle size distribution of dispersive thing in mutually.Do not consider apparent viscosity, exist the elastomer of slight yield stress or low shear rate can reduce lasting stability yet.Can calculate the critical particle diameter by yield value of stress.Under the situation of isolating spheroidal particle, the maximum shear stress that precipitation produces in the medium of given viscosity is as follows:
τ
Maximum=3V μ/2r.
With regard to pseudoplastic fluid, the zero shear viscosity characterization the when viscosity in this shear stress scheme just in time is newton's platform (Newtonian plateau).
To inject the premix compositions of thin film casting machine for preparation, thereby and the stability of keeping the wet film stage form abundant solid form up to intensive drying with locking granule and substrate and keep homogeneity, steady suspension is an important feature.With regard to viscoelastic fluid system, the rheology that can obtain long-time as 24 hours stable suspension must balance each other with the demand to the high-speed film pouring operation.Ideal film should have shear thinning or pseudoplastic characteristics, and thus, viscosity can reduce with the increase of shear rate.Time dependence shear effect for example thixotropy also is favourable.Structural recovery and shear thinning behavior are key properties, make film have the ability that the oneself evens up when forming.
The rheology condition of the present composition and film is very strict.This is because of the stable particle suspension liquid of generation, for example 30-60 weight % in the viscoelastic fluid substrate that need all have the acceptable viscosity value in big range of shear rate.May experience 10-10 between mixing, suction and thin film casting cycle
5Second
-1Shear rate, pseudoplastic behavior is a preferred implementation.
When thin film cast or coating,, also be a limiting factor therefore because rheological characteristic has the ability that forms required uniformity film.Shear viscosity, tensile viscosity, viscoelasticity, structural recovery can influence the quality of film.The illustrative example of pseudoplastic fluid of evening up shear thinning is as follows:
α
(n-1/n)=α
o (n-1/n)-((n-1)/(2n-1))(τ/K)
1/n(2π/λ)
(3+n)/nh
(2n+1)nt
Wherein α is the surface wave amplitude, α
oBe initial amplitude, λ is the wavelength of surface roughness, and " n " and " K " all is viscosity power law index.In this example, the behavior of evening up is relevant with viscosity, with the reducing and increase of n, reduces with the increase of K.
Ideally, film of the present invention or film-forming composition can very fast recovery structures, that is, behind treated formation film, it can disintegrate or produces discontinuous aspect its structure and component uniformity.This structural very fast recovery can slow down solids precipitation and deposition.And ideal film of the present invention or film-forming composition are the pseudoplastic fluids of shear thinning.Consider the fluidic characteristic of this class, for example viscosity and elasticity can promote the formation and the uniformity of thin film.
Therefore, the uniformity of component mixture depends on many variablees.As described herein, the rheological behavior of the viscosity of described component, hybrid technology, the blend compositions that makes and wet casting film all is an importance of the present invention.In addition, also to further consider controlling particle size and grain shape.Ideal particle size is 150 microns or littler, for example 100 microns or littler.And this class granule can be spherical, and substantially spherical or non-sphere are as irregularly shaped particles or oval granule.It is desirable to oval granule or ellipsoid,, thereby can be maintained in the uniformity of membrane matrix because their sedimentary tendencies are lower than the precipitation tendency of spheroidal particle.
Can adopt many technology to prevent from telolemma, to carry bubble secretly at mix stages.In order to be provided at the composition mixture that does not have bubble formation in the final products basically, can adopt anti-foaming agent or surface tension reducer.In addition, preferably can also control mixing velocity, prevent from gas inspiration mixture is formed cavitation.At last, can also bubble be overflowed reduce bubble by before the film drying, mixture being left standstill sufficiently long a period of time.Ideal the inventive method is at first to form the film-forming components masterbatch that does not contain active component such as drug particles or volatile material such as flavored oils.Before being about to pour into a mould, described activating agent is added in the less masterbatch mixture.Therefore, described masterbatch premix can leave standstill the long period and need not to consider the unstability of medicine or other composition.
When formation contains film forming polymer and polar solvent, when also having the substrate of other additive and active component in addition, can finish through many steps.For example, whole compositions can be added together or can prepare premix.The advantage of premix is that all the components except activating agent can make up in advance, is being about to just to add activating agent before the film forming.This activating agent that can degrade to Long contact time water, air or another kind of polar solvent is even more important.
Fig. 6 shows a kind of be suitable for preparing premix, adding activating agent and film forming subsequently equipment 20.The described premix or the masterbatch 22 that will comprise film forming polymer, polar solvent and any other additive except that pharmaceutically active agents add masterbatch feed well 24.Should in the blender (not shown), form each component of premix or masterbatch 22, and then add in the masterbatch feed well 24.Then, with the masterbatch of scheduled volume through first dosing pump 26 and control valve 28 controlled give expect first and/or second blender 30,30 '.Yet, the present invention be not limited to adopt two blenders 30,30 ', can adopt any amount of blender suitably.And, the present invention be not limited to blender 30,30 ' any particular sorted, can adopt suitably as shown in Figure 6 parallel ordering and other ordering or the arrangement of blender, as parallel and successive series or combination.With the medicine of aequum or other composition such as flavoring agent by each blender 30,30 ' opening 32,32 ' addings expect in the blender.Hope can make premix or masterbatch 22 blender 30,30 ' in holdup time the shortest.Although medicine is disperseed in premix or masterbatch 22 fully, the long holdup time can make medicine leach or dissolving, and is especially true to soluble agents.Therefore, blender 30,30 ' littler than the elementary blender (not shown) that is used to form premix or masterbatch 22 usually can shorten the holdup time.Medicine mix with the masterbatch premix be enough to a period of time of even substrate is provided after, with a certain amount of even substrate through second dosing pump 34,34 ' be fed to dish 36.Described metering roll 38 has determined the thickness of film 42, and it is delivered to application roll.Final described film 42 is shaped on base material 44, transports through backing roll 46.
Though the appropriate viscosity uniformity of mixture and stable particle suspension and pouring procedure in the initial step that forms compositions and film to promoting that uniformity is very important, yet it is important too that wet film is carried out exsiccant method.Although these parameters and characteristic help initial uniformity,, when controlled quickly drying method can guarantee to make uniformity to remain to the film drying.
Then, ideal situation is not have outer gas stream on the end face (exposure) 48 at film as described herein or not under its condition that heats, adopt the dry wet film of the dry or controlled method for microwave drying in controlled bottom.Dry or the controlled microwave drying in controlled bottom can advantageously make the film released vapour and avoid the shortcoming of prior art.The conventional convection current air drying that begins from the top can make film begin drying from topmost, hinders fluid together as the steam of evaporation and the mobile barrier of hot-fluid such as dry heat energy thereby form, thereby can not adopt.The further release of steam when the exsiccant top section of this class hinders dry bottom portion as barrier, thus the heterogeneity film obtained.As mentioned above, some top stream can be with helping dry film of the present invention, but it can not cause can cause cause heteropical granule to move or film in the condition of chain reaction.If adopt the top air, it must balance each other with the bottom air drying and avoid heterogeneity and prevent that film from arching upward on transport tape.When the bottom air-flow plays main dry source, and top stream plays the time spent of doing of less important dry source, and top and bottom air-flow be balance suitably.The advantage of some top stream is to remove the steam of discharge from film, thereby helps whole dry run.Yet the exsiccant utilization in any top stream or top all needs the many factors of balance, includes but not limited to: the rheological characteristic of compositions and processed are in the factor of mechanical aspects.Also necessarily require flowing of any top fluid (as air) all can not suppress as described in the intrinsic viscosity of film-forming composition.In other words, described top stream can not be destroyed, be twisted or the surface of the described compositions of Physical Interference otherwise.And ideal air velocity will be lower than the yield value of film,, is lower than any level of force that can be moved into the liquid in the film composition that is.With regard to thin or low viscous compositions, must adopt low-flow speed.With regard to stiff or full-bodied compositions, can adopt higher air velocity.And, thereby lower can avoid the film made by compositions any of ideal air velocity arches upward or other moves.
And film of the present invention can contain the temperature sensitivity granule, as being volatile flavoring agent, maybe can have the medicine of low degraded temperature.At this moment, can reduce baking temperature and prolong suitable dry uniform films of the present invention drying time simultaneously.And, to compare with the top drying, the bottom drying also can cause lower temperature in the shed.Compare with the top drying, when the bottom is dry, evaporated vapor can be more easily with the heat band from film, thereby reduce temperature in the shed.The temperature in the shed that this class is lower can cause that usually drug degradation reduces and the loss of some volatilizer such as flavoring agent reduces.
And, can also after the cast of compositions or mixture is formed film, granule or microgranule be added in described film-forming composition or the substrate.For example, can be before desciccator diaphragm 42 granule be added film 42.Controllably granule is added on the film with measuring, makes it to be deposited on the film, granule is deposited on the film surface with controlling as the scraper (not shown) device of touching or touch the film surface by utilization gently at the edge by suitable technique.Other suitable but nonrestrictive technology comprises: utilizes and extends roller granule is placed on the film surface, and particle jetting is first-class to the film surface.Described granule can place on the one or both sides on film surface, that is, and and the end face on film surface and/or bottom surface.Ideal situation is that granule firmly is arranged on the film, as embedding in the film.And, fully embedding or embed in the film fully of this class granule in the ideal situation, but still be exposed to the film surface, as be partially submerged into or the situation of part embedded particles.
Described granule can be any useful organ sensation's agent, enamel, medicament or its combination.Ideal medicament is to hide medicament taste or controlled release.Useful organ sensation's agent comprises flavoring agent and sweeting agent.Useful enamel comprises breath freshener or Decongestant, as menthol, comprises the menthol crystal.
Although the inventive method is not limited to any exsiccant concrete instrument of above-mentioned ideal that can be used for, a kind of concrete useful drying instrument 50 as shown in Figure 7.Drying instrument 50 is the nozzle arrangement that hot fluid (such as but not limited to hot-air) guiding are positioned at film 42 bottoms on the base material 44.Hot-air enters the entrance point 52 of described drying instrument, moves toward air deflector 56 vertically upward as described in vector 54.The direction that described air deflector 56 change air move makes the upward force minimum to film 42.As described in Figure 7, when air flow through air deflector 56, enter and the chamber portion 58 and 58 ' time of the described drying instrument 50 of flowing through, air as vector 60 and 60 ' shown in be oriented in a tangential direction.Thermal current is tangent line with film 42 basically, thereby the probability that film arches upward when making drying reduces to minimum.Although illustrated air deflector 56 is rollers, also suitable other device and the geometry of adopting come local derviation air or hot fluid.And, the port of export 62 and 62 of described drying instrument 50 ' open downwards.This open downwards provide as vector 64 and 64 ' shown in downward power or downward velocity vector, thereby help to provide tractive or drag interaction to prevent that film 42 from arching upward to film 42.Arching upward of film 42 not only can cause non-homogeneous shape in film, can also cause that film 42 and/or base material 44 arch upward and make the processing of film 42 uncontrolled from process equipment.
Monitoring and controlling diaphragm thickness can provide the film of uniform thickness, thereby also help to produce uniform films.The thickness of film can be monitored with gauge such as beta thickness gauge (Beta Gauge).Gauge can be the terminal coupling of drying oven or drying tunnel at drying instrument with another gauge, is communicated with the opening of controlling and regulate applicator through feedback circuit, thus the uniformity of controlling diaphragm thickness.
Usually polymer and polar solvent by will suitably selecting, and required any active component or filler make up and prepare described film product.Solvent in the desirable combination accounts for total combination at least about 30 weight %.Should the substrate that this is combined to form be made film by roller coat, should carry out dry uniformity with the maintenance film by quick and controlled drying means then, more specifically say, be that non-self aggregation is evenly heterogeneous.The film that obtains should contain the following solvent of 10 weight % of having an appointment, the solvent that more desirably about 8 weight % are following, even following solvent and the following solvent of most desirably about 2 weight % of more desirably about 6 weight %.Described solvent can be water, polar organic solvent, includes but not limited to: ethanol, isopropyl alcohol, acetone, dichloromethane or its any combination.
Above-mentioned parameter also can influence the material selection of different component of the present invention such as but not limited to the consideration of rheological characteristic, viscosity, mixed method, pouring procedure and drying means.And the consideration that this class is selected suitable material makes the present composition, comprises medicine and/or beauty treatment dosage form or film product, and the medicine in the per unit area and/or the difference of cosmetic activity agent are no more than 10%.In other words, be no more than 10 weight % by the difference that makes the medicine that exists in the whole substrate and/or cosmetic activity agent and determine uniformity of the present invention.Ideally, described difference is below the 5 weight %, below the 2 weight %, below the 1 weight % or below the 0.5 weight %.
Film forming polymer
Described polymer can be water solublity, water-swellable, insoluble polymer, or the combination of one or more water solublity, water-swellable or insoluble polymer.Described polymer can comprise cellulose or cellulose derivative.The object lesson of useful water-soluble polymer includes but not limited to: poly(ethylene oxide) (PEO), amylopectin, hydroxypropyl emthylcellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, Polyethylene Glycol, xanthan gum, Tragacanth, guar gum, acacin, arabic gum, polyacrylic acid, methylmethacrylate copolymer, carboxy vinyl co-polymer, starch, gelatin and combination thereof.In some embodiments, adopt the combination of PEO and cellulosic polymer (as hydroxypropyl cellulose).The object lesson of useful insoluble polymer includes but not limited to: ethyl cellulose, Cellulose ethyl hydroxypropyl ether, cellulose acetate-phthalate, Hydroxypropyl Methylcellulose Phathalate and combination thereof.
Phrase used herein " water-soluble polymer " and variant thereof refer to be partially soluble at least water, preferably fully or most of water-soluble or absorb the polymer of moisture.The polymer that absorbs moisture is often referred to the water-swellable polymer.The used material of the present invention can have water solublity or water-swellable in room temperature and other temperature when being higher than room temperature.And described material can have water solublity or water-swellable under pressure below atmospheric pressure.Ideally, described water-soluble polymer is water solublity or the water-swellable polymer with at least 20 weight % water intakes.Also can adopt the water-swellable polymer of water intake with 25 weight % or higher percentage ratio.Film of the present invention or the dosage form made by this class water-soluble polymer should have enough water solublity, can dissolve when contacting with body fluid.
Other polymer that can be used for mixing film of the present invention comprises biodegradable polymer, copolymer, block polymer and combination thereof.The known useful polymer or the type of polymer that satisfy above-mentioned standard are: poly-(glycolic) (PGA), poly-(lactic acid) (PLA), poly-diox, poly-oxalate, poly-(α-ester), polyanhydride, poly-acetas, polycaprolactone, poly-(ortho esters), polyamino acid, poly-amino-carbon acid esters, polyurethane, Merlon, polyamide, poly-(alkyl cyanoacrylate) and composition thereof and copolymer.Other useful polymer comprises, the space polymers of L-and D-lactic acid, the copolymer of two (right-the carboxyl phenoxy group) propanoic acid and decanedioic acid, the decanedioic acid copolymer, caprolactone copolymer, poly-(lactic acid)/poly-(glycolic)/ethylene glycol copolymer, the copolymer of polyurethane and (poly-(lactic acid)), the copolymer of polyurethane and poly-(lactic acid), the copolymer of a-amino acid, the copolymer of a-amino acid and caproic acid, the copolymer of α-benzyl glutamic acid and Polyethylene Glycol, the copolymer of succinate and poly-(ethylene glycol), polyphosphazene, poly-hydroxyl-alkanoate and composition thereof.Binary and ternary system have also been considered.
Other concrete available polymer comprises with trade name Medisorb and those commercially available polymer of Biodel.Described Medisorb material can be designated as " poly (lactide-co-glycolide) " that contain " the 2-hydroxy polymer of propanoic acid, hydroxyl polymer-containing and hydroxyacetic acid " usually available from the E.I.Du Pont Company (Dupont Company) of Wilmington City, Delaware, USA State.4 kinds of these base polymers comprise lactide/glycolides 100L, think to have 338-347 100% lactide of fusing point of (170-175 ℃); Lactide/glycolides 100L, think to have 437-455 100% Acetic acid, hydroxy-, bimol. cyclic ester of fusing point of (225-235 ℃); Lactide/glycolides 85/15, think to have 338-347 85% lactide and 15% Acetic acid, hydroxy-, bimol. cyclic ester of fusing point of (170-175 ℃); And lactide/glycolides 50/50, think to have 338-347 50% lactide of fusing point of (170-175 ℃) and the copolymer of 50% Acetic acid, hydroxy-, bimol. cyclic ester.
Described Biodel material is represented the different polyanhydrides material of all kinds of chemical property.
Although can adopt various polymer, wish that selective polymer provided the viscosity of expection for mixture before drying.For example, if activating agent or other component are insoluble to selected solvent, then need to provide more full-bodied polymer to help keep uniformity.On the other hand, if described component dissolves in solvent, then preferably provide more low viscous polymer.
Described polymer has played important function aspect the film viscosity influencing.Viscosity is a kind of characteristics of liquids of the stability of control activating agent in Emulsion, colloid or suspension.Usually the viscosity of substrate changes in 000 centipoise at about 400-100, preferably is about 800-60,000 centipoise be most preferably 1,000-40,000 centipoise.Ideal one-tenth membrane matrix viscosity can increase after the beginning dry run fast.
Can regulate described viscosity according to the activating agent of selecting according to other component in the substrate.For example, if described component is insoluble to selected solvent, then can select suitable viscosity in case described component precipitation consequently influences the uniformity that makes film unfriendly.Can regulate described viscosity with different modes.In order to increase the viscosity of membrane matrix, can select to have more high molecular weight polymers or can add cross-linking agent, as calcium salt, sodium salt and potassium salt.Can regulate viscosity by attemperation or by adding viscosity increasing component.The component that can increase viscosity or stable emulsion/suspension comprises more high molecular weight polymers and polysaccharide and colloid, includes but not limited to: alginate, carageen polysaccharide, hydroxypropyl emthylcellulose, locust bean gum, guar gum, xanthan gum, dextran, arabic gum, gellan gum and combination thereof.
Also observe, some polymer that needs plasticizer could obtain the flexible film when using separately usually can combine, and also can obtain the flexible film when not needing plasticizer.For example, can obtain to have suitable plasticity and elasticity when coupling HPMC and HPC and be convenient to the flexible robust thin film making and preserve.Its flexible acquisition does not need other plasticizer or polyhydric alcohol.
Release-controlled film
Term " controlled release " refers to that activating agent discharges with the speed of chosen in advance or expection.This speed can change according to purposes.Ideal speed comprises fast or moderate release profiles and delay, continue or discharge in succession.Also considered the combination of release mode, strengthened release during as beginning, then reduced levels continues release bioactive agent.Also considered the pulsed drug release.
The polymer that is selected for film of the present invention can also make controllably disintegrate of activating agent.Can realize by the water-insoluble basically film that has mixed a period of time of after the activating agent that can discharge in the film is provided.Can realize by mixing various solubility or insoluble polymer, can also contain biodegradable polymer in the combination.Perhaps, the controlled release active particle through coating can be mixed in the easy molten membrane matrix, thereby after picked-up, realize the controlled release attribute of activating agent in digestive system.
Can provide the film of controlled release activating agent especially suitable in oral cavity, gingival sulcus, Sublingual and vaginal application.Because film of the present invention can be easily moistening on the ground that has mucosa or mucosa liquid and be adhered on it, thereby is particularly useful for these places.
Drug world recognizes for a long time, and giving can be more more convenient than giving repeatedly single dose with regular intervals with the single dose of drug of the long-time release of active ingredients of mode of control.Recognize that also it has the advantage of the blood Chinese medicine level that can keep lasting and stable for a long time to patient and clinician.The advantage of various sustained release formses is many known.Yet the manufacture method of the film of energy controlled release activating agent also has other advantage except the advantage of those known controlled-release pharmaceutical tablets.For example, owing to need not swallow thin film as tablet, so it is not easy to be sucked trachea absent-mindedly, thereby has increased patient's compliance.And some embodiment of film of the present invention is designed to adhere to oral cavity and tongue and control ground dissolving there.And thin film can not broken into pieces as controlled-release pharmaceutical tablet, thereby has avoided the abuse problem of medicine such as OxyContin.
The activating agent that the present invention adopts can mix in the film composition of the present invention of controlled release forms.For example, granule medicament can be used polymer (as respectively with trade name such as Aquacoat ECD and commercially available ethyl cellulose or the polymethacrylates of Eudragit E-100) coating.Drug solution also can be adsorbed onto on the polymeric material and mix in the film composition of the present invention.Other component such as fat and wax, and sweeting agent and/or flavoring agent also can be used in this class controlled release composition.
Described activating agent can hide through the sense of taste before mixing film composition, (be pursuant to the identical U.S. Provisional Application number express label of title that JIUYUE in 2003 was submitted on the 27th: EU552991605 US as the PCT application that is entitled as UniformFilms For Rapid Dissolve Dosage Form Incorporating Taste-Masking Compositions (mixing the uniform films that the sense of taste hides the rapid-dissolve dosage form of compositions) of awaiting the reply jointly, agent's docket number: 1199-15P) described, it is for referencial use to include this paper in full in it.
Activating agent
When activating agent is imported film,, therefore can determine the amount of activating agent described in the per unit area because film is equally distributed.For example, when film is cut into each dosage form, can very accurately know the amount of the activating agent in the described dosage form.This be because in the particular area amount of activating agent basically with another part film in the onesize area amount of activating agent identical.When described activating agent is a medicament when being medicine, the accuracy of dosage is especially favourable.
The active component that can mix film of the present invention includes but not limited to: medicinal and cosmetic activity agent, medicine, medicament, antigen or anaphylactogen such as ragweed pollen, brood cell, microorganism comprise that antibacterial, seed, oral cavity clean component such as chlorate or chlorite, flavoring agent, spice, enzyme, antiseptic, sweeting agent, coloring agent, spice, vitamin and combination thereof.
The active substance and the pharmaceutical composition that can contain various medicaments, biologically active in the dosage form of the present invention.The example of useful medicine comprises the ACE-inhibitor, anti-anginal drug, anti-arrhythmic, antasthmatic, anti-cholesterol medicine, analgesic, anesthetis, anticonvulsant, antidepressants, antidiabetic drug, anti-diarrhoeic prod, antidote, hydryllin, antihypertensive, the antibiotic medicine, the antilipoid medicine, anti-manic medicine, antinanseant, Aggrenox, the antithyroid goods, antineoplastic agent, antiviral agents, the acne medicine, alkaloid, products of amino acid, cough medicine, antigout drug (anti-uricemic drug), antiviral agents, short anabolism goods, whole body and non-general anti-infective, antineoplastic agent, antiparkinsonism drug, antirheumatic, appetite stimulator, biological response modifier, Hemoregulatory, the bone metabolism regulator, cardiovascular drug, central nervous system's stimulant, cholinesterase inhibitor, contraceptive, decongestant, food additive, dopamine-receptor stimulant, the endometriosis controlling agent, enzyme, remedial agent for erectile dysfunction, fertility factor, gastrointestinal drug, homeopathic therapeutic method's agent, hormone, hypercalcemia and hypocalcemia controlling agent, immunomodulator, immunosuppressant, migraine agent, the motion sickness therapeutic agent, muscle relaxant, obesity control agent, the osteoporosis agent, oxytocic, parasympatholytic, parasympathomimetic agent, prostaglandin, psychotherapy's agent, breathe agent, analgesic, smoking deterent such as bromocriptine and nicotine, sympatholytic, medicine trembles, the urinary tract medicine, vasodilator, laxative, antacid, ion exchange resin, antipyretic, appetite suppressant, expectorant, antianxiety drugs, antiulcerative, anti-inflammatory agent, coronary artery dilator, the brain expander, peripheral vasodilator, intend neurologic agent, analeptic, antihypertensive, vasoconstrictor, the migraine treatment agent, antibiotic, tranquilizer, psychosis, antineoplastic agent, anticoagulant, antithrombotic, sleeping pill, Bendectin, antinauseant, anticonvulsant, neuromuscular drug, blood glucose increasing and blood sugar lowering, thyroid and antithyroid drug, diuretic, spasmolytic, agent is speeded to delay in the uterus, antiadipositas drug, promoting erythrocyte generates medicine, antasthmatic, anti-tussive agents, mucolytic, DNA and genetic modification medicine and combination thereof.
Through considering that the example that can be used for active constituents of medicine of the present invention comprises antacid, H
2-antagonist and analgesic.For example, can singly prepare and separate acid supplement with the calcium carbonate composition or with magnesium hydroxide and/or aluminium hydroxide coupling.And, antacid can with H
2The coupling of-antagonist.
Analgesic comprises Opiate and opium derivant, as oxycodone (with
Commercially available), ibuprofen, aspirin, acetaminophen and or choosing contain the combination of caffeine.
Can be used for other preferred agents of the present invention as other preferred active component and comprise diarrhea medicine such as imodium AD, hydryllin, cough medicine, decongestant, vitamin and breath freshener.This paper considers that the suitable vitamin that uses comprises the known vitamin of any routine, such as but not limited to: vitamin A, B, C and E.Can contain Chang Danyong or coupling in the film composition of the present invention and treat flu, pain, fever, cough, hyperemia, runny nose and hypersensitive medicine, as acetaminophen, chlorphenamine maleate, dextromethorphan, pseudoephedrine HCl and diphenhydramine.
This paper also consider to use antianxiety drugs such as alprazolam (with
Commercially available); Psychosis such as Crow azoles flat (clozopin, with
Commercially available) and haloperidol (with
Commercially available); Non-steroid antiinflammatory drug (NSAID) as the bicyclo-chlorfenac (with
Commercially available) and etodolac (with
Commercially available), hydryllin such as loratadine (with
Commercially available), astemizole is (with Hismanal
TMCommercially available), nabumetone (with
Commercially available) and clemastine (with
Commercially available); Bendectin example hydrochloric acid granisetron (with
Commercially available) and nabilone (with Cesamet
TMCommercially available); Bronchodilator as
Salbutamol sulfate (with
Commercially available); Antidepressants example hydrochloric acid fluoxetine (with
Commercially available), sertraline hydrochloride (with
Commercially available) and paroxetine hydrochloride (with
Commercially available); Antimigraine as
ACE-inhibitor such as enalaprilat (with
Commercially available), captopril (with
Commercially available) and lisinopril (with
Commercially available); Sick medicine of Kang Aercihaimoshi such as nicergoline; And Ca
H-antagonist such as nifedipine (with
With
Commercially available) and verapamil hydrochloride (with
Commercially available).
Remedial agent for erectile dysfunction includes but not limited to: can promote blood to flow to penis and influence the autonomic nerve activity, if can increase parasympathetic nervous (cholinergic) and the active medicine of minimizing sympathetic nerve (Adrenergic).Useful non-limiting medicine comprise 'Xiduofeng ' as
Non-in it reaches (tadalafils) as
Vardenafil, apomorphine as
Yohimbine Hcl as
With Alprostadil as
Consider to be used for H commonly used of the present invention
2-antagonist comprises that Cimetidine, ranitidine hydrochloride, famotidine, nizatidine, ebrotidine, mifentidine, roxatidine, a sand are for fourth and roxatidine.
Active antacid composition includes but not limited to following: aluminium hydroxide, dihydroxyaluminum aminoacetate, glycine, aluminum phosphate, mincid, bicarbonate, bismuth aluminate, waltherite, bismuth subcarbonate, bismuth subgallate, basic bismuth nitrate, basic bismuth salicylate, calcium carbonate, calcium phosphate, citrate ion (acid or salt), glycine, Magnesium sulfate heptahydrate aluminum (hydrate magnesium aluminate sulfate), magaldrate (magaldrate), almasilate (magnesium aluminosilicate), magnesium carbonate, magnesium glycinate, magnesium hydroxide, magnesium oxide, magnesium trisilicate, milk solids (milk solid), aluminum phosphate one calcium or aluminum phosphate dicalcium (aluminum mono-ordibasic calciumphosphate), tricalcium phosphate, potassium bicarbonate, sodium tartrate, sodium bicarbonate, almasilate, tartaric acid and salt.
The pharmaceutically active agents that the present invention adopts can comprise anaphylactogen or antigen, such as but not limited to: the plant pollen of grass, tree or artemisiifolia; The animal scurf is promptly from the skin of cat and other fur-bearing animal and the little squama of alopecia; Insecticide is as dermatophagoides pteronyssinus, Apis and wasp; And medicine, as penicillin.
Can also add plant, medicinal herbs and mineral in the film.The example of plant includes but not limited to: root; Skin; Leaf; Stem; Flower; Fruit; Nicotiana tabacum L.; The Helianthi seed; Folium Nicotianae preparatum palm fibre (snuff) and combination thereof.
Antioxidant can also be added film to prevent especially heliosensitivity activating agent degraded of activating agent.
The described bioactive substance that the present invention adopts can comprise probiotics.Say that more specifically normal presence is in some antibacterial of tongue surface and throat back.This bacterioid is helped digest food by the protein that decomposes in the food.Therefore, ideal situation is that these antibacterials are mixed oral cavity of the present invention with in the film product.
Ideally also comprise the activating agent of treatment halitosis and relevant oral care disease, if can effectively suppress the activation of microorganism agent.Because halitosis may be owing to existing the anaerobe that can produce volatile sulfur compounds to cause in the oral cavity, therefore ideally can adopting the component that can suppress this quasi-microorganism.The example of this class component comprises antibacterial, as triclosan, chlorine dioxide, chlorate and chlorite etc.Using chlorite in oral care composition such as mouthwass and toothpaste specifically is that the method for sodium chlorite can be referring to United States Patent (USP) 6,251,372,6,132,702,6,077,502 and the U.S. disclose 2003/0129144, it is for referencial use all to include this paper in full in it.This class component is mixed with the effective dose of treatment halitosis and relevant oral disease.
The cosmetic activity agent can comprise breath freshening chemical compound such as menthol, and other flavoring agent or spice are in particular for those chemical compounds of oral hygiene, and the activating agent such as the quaternary ammonium base that are used for tooth and oral cavity cleaning.Can use seasoning reinforcing agent such as tartaric acid, citric acid, vanillin to wait the effect that strengthens flavoring agent.
Coloring agent also can be used to prepare film.This based colorant comprises food, medicine and cosmetics coloring agent (FD﹠amp; C), medicine and cosmetics coloring agent (D﹠amp; Or topical drug and cosmetics coloring agent (Ext.D﹠amp C); C).These coloring agent are dyestuffs, their corresponding color lakes, and some natural and deutero-coloring agent.The color lake is the dyestuff that is absorbed on the aluminium hydroxide.
Other example of coloring agent comprises known azo dye, organic or inorganic pigment, or the coloring agent of natural origin.Preferred inorganic pigments, as ferrum or titanyl compound, these oxides are with about 0.001-10% of all components weight, and preferably the concentration of about 0.5-3% adds.
Can select natural or synthetic baste to serve as flavoring agent.The extract that comprises volatile oil, synthetic flavored oils, seasoning aromatic, oil, liquid, oleoresin or plant, leaf, flower, fruit, stem and combination thereof in the illustrative list of this class material.Comprise Oleum menthae, cocoa and citrus oils such as Fructus Citri Limoniae, orange, Fructus Vitis viniferae, Citrus aurantium Linn. and grapefruit in the non-limiting and representative example tabulation, and the fruit elite comprises Fructus Mali pumilae, pears, peach, Fructus Vitis viniferae, Fructus Fragariae Ananssae, Fructus Rubi, Fructus Pruni pseudocerasi, Lee, Fructus Ananadis comosi, Fructus Pruni or other fruity flavoring agent.
Can add the film that contains flavoring agent thereby heat or cold beverage or soup through seasoning is provided.These flavoring agents include but not limited to: tea and soup flavoring agent be beef and Carnis Gallus domesticus taste for example.
Other useful flavoring agent comprises aldehyde and ester, as benzaldehyde (Fructus Pruni pseudocerasi, Semen Armeniacae Amarum), citral is α citral (Fructus Citri Limoniae, a Citrus aurantium Linn.), neral, that is, β citral (Fructus Citri Limoniae, Citrus aurantium Linn.), n-capric aldehyde (orange, Fructus Citri Limoniae), aldehyde C-8 (citrus fruit), aldehyde C-9 (citrus fruit), aldehyde C-12 (citrus fruit), tolyl aldehyde (Fructus Pruni pseudocerasi, Semen Armeniacae Amarum), 2,6-dimethyl octanol (green fruit) and 2-laurylene aldehyde (Citrus, Fructus Citri tangerinae) and combination thereof etc.
Described sweeting agent can be selected from following non-limiting tabulation: glucose (corn syrup), dextrose, Nulomoline, fructose and combination thereof; Glucide and its various salt are as sodium salt; Dipeptide sweetener is as the aspartame; Dihydrochalcone chemical compound, glycyrrhizin;
Stevia Rebaudiana(Stevioside); The chlorinated derivative of sucrose is as sucralose; Sugar alcohol is as Sorbitol, mannitol, xylitol etc.It is also conceivable that hydrogenated starch hydrolysates and synthetic sweetener 3,6-dihydro-6-methyl isophthalic acid-1-1,2,3-Evil thiazine-4-ketone-2, the 2-dioxide specifically is the sweeting agent of its potassium salt (acesulfame potassium) and sodium thereof and calcium salt and natural reinforcement, as Lo Han Kuo.Also can use other sweeting agent.
When activating agent mixed in solvent with polymer, formed matrix type depended on the dissolubility of described activating agent and polymer.If described activating agent and/or polymer dissolve in selected solvent, can form solution so.Yet if described component is soluble, substrate can be divided into Emulsion, colloid or suspension so.
Dosage
It is very wide that film product of the present invention can hold the quantitative range of active component.No matter required dosage is high or extremely low, and film can both provide exact dose (size and the initial concentration of activating agent in polymer/water combination by film are determined).Therefore, according to the type of activating agent that mixes film or pharmaceutical composition, described active dose can should or be low to moderate the microgram scope up to about 150mg up to about 300mg, or any amount between them.
The high homogeneity of film has determined film product of the present invention and method to be very suitable for dynamical low-dose drugs.Therefore, should adopt low-dose drugs, especially have more the racemic mixture of the activating agent of usefulness.
Anti-tacking compositions
Can add antiplastering aid in the film composition of the present invention in the past, as lubricant, antitack agent and fluidizer.Antiplastering aid can be for example by reducing in the extrusion process with the adhesion of mould and reducing when giving described dosage form and the adhesion of oral cavity maxillary helps improve the fluid properties of material.
When using film, granule adheres on the maxillary of oral cavity easily.This is unfavorable for the film that contains bitterness medicine such as dextromethorphan, and this is because adhered particles is left medicine and can be made user feel more bitter.Add that antiplastering aid can reduce and the adhesion of oral cavity maxillary in the film, thus the bitterness of feeling when effectively alleviating the user use.
Antiplastering aid can also reduce film and intermembranous coefficient of friction, is the problem that the film bar sticks to each other thereby alleviate membrane amount unit.Say that more specifically in multiple film packing, the film bar piles up each other.Mix antiplastering aid and can make when in packing, taking out each unit, can slide glibly each other between each film bar.
The example that can be used as the proper lubrication agent of antiplastering aid includes but not limited to: stearate, as magnesium stearate, calcium stearate and sodium stearate; Stearic acid; Hydrogenated vegetable oil; Talcum; Wax; Stearoyl stearowet; Boric acid; Sodium benzoate; Sodium acetate; Sodium chloride; The DL-leucine; Macrogol 4000; Polyethylene glycol 6000; Enuatrol; Sodium lauryl sulfate; Lauryl sulfate magnesium and combination thereof.
The example of suitable antitack agent includes but not limited to: Talcum; Corn starch; Cab-O-Sil; Gas phase micropowder silica gel (syloid); The DL-leucine; Sodium lauryl sulfate; Metallic stearate and combination thereof.The example of suitable glidant includes but not limited to: Talcum; Corn starch; Cab-O-Sil; The gas phase micropowder silica gel; Aerosol and combination thereof.
Some embodiments of the present invention comprise uses fat and/or wax as antiplastering aid.
Use vitamin E as the suitable antiplastering aid of another kind in some embodiments of the present invention.Vitamin E can be simultaneously as active component in antiplastering aid and the film.Should adopt vitamin E TPGS (dextrorotation alpha tocopherol cetomacrogol 1000 succinate).Vitamin E TPGS is a kind of watermiscible vitamin E derived from natural origin.Compare with its other form, vitamin E TPGS is easier to absorb.In addition, vitamin E TPGS can bring taste to film hardly.Vitamin E TPGS can be used for solution, for example 10% or 20% aqueous solution.Vitamin E TPGS is particularly useful for reducing film viscosity, makes it to be not easy to adhere on the oral cavity maxillary of user.The content of vitamin E can account for the 0.01-20% of composition weight.
The content of antiplastering aid accounts for the 0.01-20% of film composition weight usually.Say that more specifically the content of antiplastering aid can account for the 0.01-10% of film composition weight, even more specifically say, account for the 0.25-5% of film composition weight.
Can also adopt the antiplastering aid combination.For example, in some embodiments of the present invention, can adopt the combination of stearate such as magnesium stearate and silicon dioxide.Particle mean size is the silica product of 4.5 μ m, and SIPERNAT500LS is applicable to herein (commercially available by Degussa).The combination of magnesium stearate and silicon dioxide can provide the fluidizer of improvement, that is, help the film bar in the packing to slide glibly each other.Therefore, in some embodiments, the content of magnesium stearate accounts for the 0.1-2.5% of film composition weight, and the content of silicon dioxide accounts for the 0.1-1.5% of film composition weight.This class combination of antiplastering aid can be used for containing in the various types of films of various flavoring agents and/or activating agent.
In some embodiments, described film composition itself just contains antiplastering aid.For example, can form the single or multiple lift film that contains antiplastering aid.Multilayer film for example, can comprise two-layer, three layers or the more multi-layered film that contact with each other basically.In some embodiments, described rete can be laminated to each other.Antiplastering aid may reside in one or more layers of multilayer film.For example, some embodiments can comprise duplicature, and wherein one deck contains antiplastering aid.Some embodiments can comprise trilamellar membrane, and wherein except that the internal layer or intermediate layer of described trilamellar membrane, each skin all contains antiplastering aid.With this, can form various dissimilar combination layers.
Perhaps, in some embodiments, the compositions that is used for the coated film outer surface can contain antiplastering aid.For example, can will wet or the antiplastering aid of dry coating (as containing sugar or sugar-free coating) form is used for film.Can adopt any conventional method (such as but not limited to: dip coated, spraying coating, dust or fluid bed) antiplastering aid coated film.Can be coated with one or more films surface.In some embodiments, described anti-stick coating can be used for base material,, but not be directly used in film itself as the film backing.When backing removes film, described anti-stick coating can adhere on the film.
Anti-foam and skimming compositions
Can also use anti-foam and/or skimming component in the film of the present invention.These components help air, as air pocket, discharge described film-forming composition.As mentioned above, this air pocket may cause forming non-homogeneous film.A kind of anti-foam that is particularly useful and/or defoaming agent are simethicone.Yet the present invention is not limited to this, can also use other anti-foam and/or defoaming agent.
Simethicone is generally used for medical field treatment baby's flatulence or stomachache.Simethicone is a kind of mixture of linear siloxane polymers of the exhaustive methylation that contains polydimethylsiloxane repetitive stable through trimethicone endcapped unit and silicon dioxide.It contains the polymethyl siloxane of 90.5-99% and the silicon dioxide of 4-7% usually.Described mixture is water-fast Lycoperdon polymorphum Vitt, translucent thick liquid.
When disperseing in water, simethicone can scatter at the water surface, forms the low surface tension thin film.Like this, simethicone can reduce the surface tension of foam gas (as foam bubble) in the solution, and they are broken.The dual function of water medium oil and alcohol has been imitated in the effect of simethicone.For example, because the density of oil-based liquid is littler than the density of aqueous solution, therefore any residual bubble all can rise to the surface and faster and more easily dissipation in oily solution.On the other hand, known alcohol/aqueous mixtures can reduce the surface tension that water density can reduce water again.Therefore, any bubble that remains in the mixed solution also can dissipate at an easy rate.Simethicone solution has the advantage of above-mentioned two aspects concurrently.It can reduce the surface energy that remains in any bubble in the aqueous solution, also can reduce the surface tension of aqueous solution.Owing to have the function of this uniqueness, make simethicone have fabulous anti-foam, can be used for physiology method (anti-flatulence) and need remove in any externalist methodology of bubble in the product.
In order to prevent to form bubble in the film of the present invention, can under vacuum condition, mix.Yet, in case described blend step is finished, film is got back under the normal atmosphere (An) condition, import gas again or make it and contact with mixture.Under many situations, minute bubbles can be residued in this polymeric adhesive solution once more.Simethicone is mixed the formation that bubble can be alleviated or eliminate to film-forming components basically.
Simethicone can about 0.01-5.0 weight %, and the better 0.05-2.5 of being about weight % and the most desirable content that is about 0.1-1.0 weight % add in the film forming mixture as antifoaming agent.
Or select component
Various other components and implant can also be added film of the present invention.These can include but not limited to: surfactant; Help to make the plasticizer of each component compatibility in the mixture; Polyhydric alcohol; Antifoaming agent, as contain the chemical compound of silicone, it creates more level and smooth film surface by making film discharge oxygen; And thermosetting cement, as pectic substance, antler glue and gelatin, help to keep each component dispersibility.
The various additives that can mix the present composition can provide various function.The example of various additives comprises excipient, lubricant, buffer agent, stabilizing agent, foaming agent, pigment, coloring agent, filler, extender, sweeting agent, flavoring agent, spice, release regulator, adjuvant, plasticizer, incremental dose, releasing agent, polyhydric alcohol, granulating agent, diluent, binding agent, buffer, absorbent, fluidizer, binding agent, antitack agent, acidulant, softening agent, resin, demulcent, solvent, surfactant, emulsifying agent, elastomer and composition thereof.These additives can add with active component.
Useful additive comprises, gelatin for example, vegetable protein such as Helianthi albumen, soybean protein, cottonseed protein, Semen arachidis hypogaeae protein, Semen Vitis viniferae albumen, lactalbumin, lactalbumin isolate, haemproteins, egg protein, the protein of acroleic acid esterification, water soluble polysaccharide such as alginate, carageen polysaccharide, guar gum, agar-agar, xanthan gum, gellan gum (gellan gum), arabic gum and relevant glue (Ficus elastica, karaya, tragacanth), pectin, water solublity derivative fibre element: alkylcellulose, hydroxy alkyl cellulose and hydroxyalkyl alkylcelluloses are as methylcellulose, hydroxy methocel, hydroxyethyl-cellulose, hydroxypropyl cellulose, hydroxyethylmethyl-cellulose, hydroxypropyl emthylcellulose, HBMC, cellulose esters and hydroxy alkyl cellulose ester such as cellulose acetate-phthalate (CAP), hydroxypropyl emthylcellulose (HPMC); Carboxyalkyl cellulose, carboxyalkyl alkylcellulose, carboxyalkyl cellulose ester such as carboxymethyl cellulose and their alkali metal salt; Water-soluble synthetic polymer such as polyacrylic acid and polyacrylate, polymethylacrylic acid and polymethacrylates, polyvinyl acetate, polyvinyl alcohol, polyvinyl acetate phthalate (PVAP), polyvinyl pyrrolidone (PVP), PVY/ vinyl acetate copolymer and poly-.beta.-methylacrylic acid; The same gelatin that also has phthalate that is fit to, gelatin succinate, cross-linked gelatin, lac, water-soluble chemical derivatized starch, cation modified acrylate and for example have uncle's amino or can be the methacrylate of tetrad when season amino (as diethyllaminoethyl), needs; With other similar polymer.
This class extender or to select addition can be any amount, ideal range is up to about 80%, ideally is about 3-50% and better scope is the 3-20% of all components weight.
Other additive can be an inorganic filler, as the oxide of magnesium, aluminum, silicon, titanium etc.Its ideal concentration is about the 0.02-3 weight % of all components weight, ideally is about 0.02-1%.
The example of other additive is a plasticizer, comprise that the concentration range to account for polymer weight 0.5-30% and ideally to be about 0.5-20% adds polyalkylene oxides, as Polyethylene Glycol, polypropylene glycol, polyethylene propylene glycol, the organic plasticizer of low-molecular-weight, as glycerol, glycerol Monoacetate, diacetin or triacetate, vinegar essence, Polysorbate, spermol, propylene glycol, Sorbitol, diethyl sulfosuccinate sodium, triethyl citrate, tributyl citrate etc.
Can also add other chemical compound and improve the flowability of starch material, as ideal situation be hydrogenated form especially at room temperature be solid animal or plant fat.The desirable fusing point of these fat is 50 ℃ or higher.Preferred C
12-, C
14-, C
16-, C
18-, C
20-and C
22The triglyceride of-fatty acid.Can not add extender or plasticizer and add separately fat, and can be advantageously add separately or with glycerol list and/or dibasic acid esters or phospholipid especially lecithin.Ideal glycerol list and dibasic acid esters are derived from above-mentioned C
12-, C
14-, C
16-, C
18-, C
20-and C
22All kinds of fat of-fatty acid.
Total consumption of fat, monoglyceride, glycerol dibasic acid esters and/or lecithin accounts for the about 5% of total composition weight at most, preferably is about 0.5-2%.
Also be suitable for adding silicon dioxide, calcium silicates or the titanium dioxide that concentration accounts for the 0.02-1% of total composition weight.These chemical compounds play the effect of thickening agent.
The consumption of these additives is enough to realize intended purposes separately.Usually, the combination of some can change the whole release profiles of active component in these additives, can be used to regulate promptly hinder or quicken discharge.
Lecithin is a kind of surfactant of the present invention that can be used for.The feeding coal of lecithin can be about 0.25-2.00 weight %.Other surfactant, i.e. surfactant includes but not limited to: spermol, sodium lauryl sulfate, ICI Americas Inc (ICI Americas, Inc) commercially available Spans
TMAnd tween
TMCan also adopt the oil of ethoxylation, comprise the Oleum Ricini of ethoxylation, commercially available as BASF AG
EL.Carbowax
TMStill the another kind of regulator very useful to the present invention.Can adopt tween
TMOr the combination of surfactant realizes required hydrophilic-lipophilic balance (" HLB ").Yet the present invention can not need to adopt surfactant, and film of the present invention or film-forming composition can be substantially free of surfactant but still can provide uniform properties required for the present invention.
Adding dextrosan in the film of the present invention can be more favourable.Dextrosan is a kind of filler and solubilizing agent, that is, its energy reinforcing membrane is at intraoral dissolution time.
The definite purpose that can improve other regulator of operation of the present invention and product of applicant is that all other regulators of this class are included in the scope of the present invention of this paper prescription.
Other composition comprises makes film be easy to be shaped and the common binding agent useful to the quality of film.The non-limitative example of binding agent comprises starch, pre-gelatinized starch, gelatin, polyvinyl pyrrolidone, methylcellulose, sodium carboxymethyl cellulose, ethyl cellulose, polyacrylamide, Ju Yi Xi oxazolidinone and polyvinyl alcohol.
Film forming
Film of the present invention must be in flakes before dry.When mix required component form comprise the multicomponent substrate of polymer, water and activating agent or other required component after, as multicomponent substrate as described in pushing, be coated with, sprawl, pour into a mould or drawing, sheet or film are made in described combination by any known method in this area.Multilayer film if desired can make up by more than one of coextrusion each component that contains identical or different compositions and realize.Can also make multilayer film by certain combination being coated with, sprawling or be poured on the rete that has been shaped.
Although can adopt various film technique, ideal situation is to select a kind of method that can prepare flexible film, as the reverse roll coating process.The pliability of film make diaphragm can preserve or cut into each dosage form before wind up and transport.In other words all right self-supporting of ideal film perhaps can not keep its integrity and structure when having independent holder.And, but film of the present invention can be selected from edible or digesting material.
In order to form film of the present invention, coating or pouring procedure are particularly useful.Especially when the needs multilayer film, concrete example comprises reverse roll coating, intaglio plate coating, immerse or dip coated, measuring stick or Meyer (Meyer) rod is coated with, slit mould or extrusion coated, crack or knife-over-roll coating (gap or knife over roll coating), airblade coating, curtain coating or its combination.
When according to the present invention during film forming, adopt print roll coating or be ideal especially more specifically for reverse roll is coated with.This method can control and make the film that obtains to have the desirable uniformity of the present invention admirably.In this method, described coating material is put on the application roll quantitatively by the slit that accurately is arranged between metering roll and its following application roll.During near described coating material is sent to application roll support roller, its can transfer to base material from application roll.3 rollers and 4 roller methods all are in daily use.
The intaglio plate coating process relies on the dandy roll that moves in the coating fluid to carry out, and rag point on the roller or the applied material of line are filled.Excessive coating material on the roller is wiped off with doctor blade, can be deposited on the base material in the time of then between coating material is by dandy roll and compression roll.
Photogravure is very common, and wherein coating material was deposited on the intermediate calender rolls earlier before transferring to base material.
Immerse or the simple procedure of dip coated in, base material is impregnated under the normal condition in the low viscous coating fluid, so as described base material when exposing liquid level coating material can flow back in the pond.
In the metering roll coating process,, base material is deposited on the base material when having excessive coating material during by the pond roller.Described wire-wound metering roll is sometimes referred to as Meyer rod (Meyer Bar), can stay the coating material of aequum on base material.Described amount is determined by the diameter of rod with line.
In the slit modeling method, arrive on the base material by gravity or under the pressure coating material being extruded slit.If coating material is 100% solid, this method just is called " squeezing and pressing method ", and in this case, linear velocity can be more much higher than extrusion speed usually.Can guarantee that like this coating layer is thin more a lot of than slot width.
In crack or the knife-over-roll method, coating material is applied on the base material, passes through " crack " between " scraper " and the support roller then.Along with passing through of coating material and base material, excess stock is scraped.
Airblade coating is that coating material is applied to base material, through the strong injection of air knife excess stock " is blown off ".This method can be used for the aqueous coating material.
In curtain formula coating process, the continuous coating material curtain that the bottom has the liquid pool generation of slit falls within two slits between conveyer belt.Object to be coated along conveyer belt with the controlled velocity process, thereby its upper surface can be received coating material.
The drying of film
Described drying steps also is to keep the inhomogeneity key factor of described film composition.When the viscosity that does not have thickening composition or compositions for example was controlled by selective polymer, component was easier to gathering or coalescent in the film, and select for use controlled drying means to be even more important this moment.Film forming or the choosing method with exact dose that need not controlled drying steps is a casting film on predetermined groove.Adopt this mode,,, can not make activating agent move to contiguous dosage form although therefore component can be assembled because each groove itself all defines dosage device.
, can realize during controlled or quickly drying method when needs by the whole bag of tricks.The whole bag of tricks that can adopt comprises those methods of needs utilization heating.Remove the liquid carrier in the striping in a certain way, to keep the uniformity that wet film has, the non-self aggregation of perhaps more specifically saying so is evenly heterogeneous.
Ideal situation is to carry out drying from the film bottom to the film top.During the primary solidification that forms the solid viscoelastic structure, ideally the film top does not have the air communication mistake basically.This can occur in several leading second in, as about 0.5-4.0 minute of drying process.The dry film end face that can prevent that the conventional drying method from often causing of control destroys and the phenomenon that forms again in this way.Can realize by forming film and it being placed on the end face on the surface with end face and bottom surface.Then, earlier the film bottom surface is heated evaporation to be provided or to remove the necessary energy of liquid carrier.Carrying out exsiccant film in this way can faster drying, even with the air drying film or compare also like this with the drying that the conventional drying means are carried out.Different with the edge with the at first dry end face of air drying film, the central authorities and the edge that carry out exsiccant film by heated base obtain drying simultaneously.Do like this and can also prevent with the normal composition deposited phenomenon that takes place of the exsiccant film of conventional means.
The film baking temperature is about 100 ℃ or lower, and ideal is about 90 ℃ or lower, the most desirablely is about 80 ℃ or lower.
Can use separately or comprise control with the method for the another kind of above-mentioned other control method coupling control drying process and regulate the interior humidity of the drying equipment of desciccator diaphragm.In this way, can avoid the too early drying of film end face.
In addition, also find suitably to control the length of drying time, promptly thermal sensitivity and the volatility with some component especially flavored oils and medicine balances each other.Can make the length and the speed of energy, temperature and conveyer belt coordinate to adapt to this activating agent mutually, and loss, degraded or ineffectivity that will telolemma drop to minimum.
The object lesson of suitable drying means is disclosed by Magoon.The method of a kind of dry pulp of Magoon specific design.Yet the inventor is used to prepare thin film with this technology.
The method and apparatus of Magoon all is based on the interesting characteristic of water.Although water can by portion within it and and the external world between conduction and convection current carry out energy delivery, water can only be in water and to the water Propagation of Energy.Therefore, the equipment of Magoon comprises that the infrared radiation of placing pulp can see through the surface.Following and the temperature control pond on described surface contacts.Described pond temperature should be controlled at the temperature a little less than the water boiling temperature.When wet pulp places on this equipment surface, produce " refractance window ".This means that infrared energy sees through the surface and can only pass to by the occupied surf zone of pulp, and can only provide energy herein up to the pulp drying.The equipment of Magoon can the accumulative efficient drying of membrane component take place in minimizing provides film of the present invention in the time.
The original depth of film is about 500-1,500 μ m, or about 20-60 mil, and dried thickness is about 3-250 μ m, perhaps is about the 0.1-10 mil.The thickness of ideal desciccator diaphragm is about the 2-8 mil, the better 3-6 mil that is about.
The utilization of thin film
Thin film of the present invention all is well suited for many application.The high homogeneity of membrane component especially is fit in conjunction with medicament them.And, can select to make film can have one period resolving time to the polymer that is used to make up film.The variation of film resolving time or prolongation can realize the control to the activating agent rate of release, thereby obtain to continue the delivery system of release.In addition, can activating agent be administered to any of multiple body surface, especially comprise the surface of mucosa with film, as in oral cavity, anus, vagina, eye, skin surface or the body as wound surface during the surgical operation and similar surfaces.
Film can be used for the orally give activating agent.Can pass through the above-mentioned film of preparation, and they be put into the mammal oral cavity finish.Can prepare film, and with its adhere to second or supporting layer on, use (promptly putting into the oral cavity) before with described film from second or supporting layer peel off.Can film be adhered on any in preferred water-fast those supports known in the art or the back lining materials with binding agent.If the use binding agent should can absorb and the food-grade adhesive that can not change activating agent character in use.The mucoadhesive compositions is particularly useful.Described film composition itself is exactly mucoadhesive in many cases.
Described film can be used for mammal Sublingual or tongue.When needing, can be preferably corresponding to the concrete film shape of tongue shape.Thereby film can be cut into corresponding to the film limit at tongue rear portion than shape corresponding to the forward film length of side of tongue.Particularly, desirable shape can be a triangle or trapezoidal.Ideal film can adhere on the oral cavity preventing that film from running out of the oral cavity, and discharges more activating agents when film dissolves in the oral cavity.
Can rapidly-soluble nature during the another kind of applications exploiting film contact liq of film of the present invention.Can pass through film produced according to the present invention, it be put into liquid make its dissolving, and activating agent is introduced liquid.This can be used for preparing the liquid dosage form of activating agent, or beverage is carried out seasoning.
Ideal situation be with film of the present invention be packaged in the packing of the secluding air of sealing and moisture with the protection activating agent can oxidation, hydrolysis, volatilization and interact with environment.As shown in Figure 1, packaged dosage units 10 comprises being packaged in the bag separately or between paper tinsel and/or the film 12 of 14 of plastics lamination sheets.As shown in Figure 2, the bag 10,10 ' can interconnect through peelable or porous seam 16.Bag 10,10 ' can be packaged into volume as shown in Figure 5 or pile up as shown in Figure 3, and sell with medicine box as shown in Figure 4.Described medicine box can contain a whole set of medicine of usually leaving at planned treatment, but thin film and packing make this medicine box littler and more convenient than the conventional bottle that is used to place tablet, capsule and medicinal liquid.And in a single day film of the present invention contacts and can dissolve immediately with saliva or mucosa district, need not water medicament is swept away.
This class dosage unit group should be packaged into together according to scheme or the treatment (as supply 10-90 days) that concrete therapy is advised.Each film can be packaged on the backing, tears off during use.
More fully embody feature and advantage of the present invention by following illustrative embodiment, and can not think restriction any way of the present invention.
Embodiment
Embodiment 1-2:
Prepare the thin, water soluble film composition with the described amount of table 1.Specifically, add vitamin E in the compositions 1 as antiplastering aid and various other component.Compositions 2 contains and compositions 1 similar component, but does not contain vitamin E.
Table 1
1Germania sweeting agent (Magna Sweet) available from Ma Fu international corporation (Mafco Worldwide Corp).
210% solution that contains 0.39g vitamin E and 3.51g water
3Available from thousand chemical company (Millennium Chemicals) N-ethyl-right-terpane-3-carboxylic acid amides coolant
4Available from three pure companies (Sentry)
Make it combination up to the thing that is uniformly mixed by mixing the above-mentioned component that is used for each compositions, pour into a mould film forming then.Specifically, with the K Control Coater that have 350 microns level and smooth rods with described solution casting to release paper (available from gray(Gy) husband paper and the (GriffPaper﹠amp of film company; Film)).Then about 80 ℃ with dry about 10 minutes of film.Compositions 1 is dried to water content is about 2.68%, compositions 2 is dried to water content is about 3.35%.
Detect the various character of described desciccator diaphragm, comprise how long and measure the pliability of film by bend test measure film by solubility test is dissolved in the oral cavity needs.In addition, observing film will present the trend of viscosity and stick at user oral cavity maxillary in the oral cavity trend on the flat board.
In order to detect rate of dissolution, the diaphragm of about 20 * 100mm of heavy 2.85g is dipped in the about 50mm depths in 32.5 ℃ the pond.Measure the film dissolving and be divided into two needed times (in second).
Also film has been carried out bend test, i.e. 180 ° of bend tests.Place moisture analyzer (available from the HR73 moisture analyzer of Ma Te Toledo (Mettler Toledo)) to obtain its moisture percentage ratio desciccator diaphragm, after 80 ℃ of dryings, remove any solvent (as water) that remains in the film according to the present invention.Then film is folded into about 180 °, observes the situation of breaking.When bending, can be defined as failure by disruptive film.If film does not break during bending, the weight of the film landing 200g from about 8.5mm eminence toward described bending.Disruptive film is confirmed as failure, and it is qualified that those do not have disruptive film to confirm as.Yet, should be noted that this flexibility test is a kind of extreme test.Still can think that the film of in test failure belongs to the interior feasible film of the scope of the invention.More specifically say, may not need the extreme pliability of this class in some applications.
Place before the moisture analyzer and afterwards compositions 1 and 2 films all show enough intensity, good resistance to rupture, and passed through 180 ° of bend tests, can with in dissolve on tongue to fast speed.The compositions 1 that contains vitamin E does not have viscosity in the oral cavity, can not adhere to user oral cavity maxillary.2 of compositionss that do not contain vitamin E are opposite.Compositions 2 shows viscosity, can adhere to the oral cavity maxillary.
Embodiment 3-243:
Be combined with as the silicon dioxide of antiplastering aid and the water-soluble film of magnesium stearate with the described content preparation of table 2.More specifically say, as shown in the table, various silicon dioxide and magnesium stearate combination are mixed in the various film composition.
Table 2
Embodiment | The kind of film | Silicon dioxide 1(weight %) | Magnesium stearate (weight %) |
3 | Acid agent (SOURS) | 1.5 | 2.0 |
4 | Acid agent (SOURS) | 1.5 | 2.0 |
5 | Acid agent (SOURS) | 1.5 | 2.0 |
6 | Acid agent (SOURS) | 1.5 | 2.0 |
7 | Acid agent (SOURS) | 1.5 | 2.0 |
8 | Acid agent (SOURS) | 1.5 | 2.0 |
9 | Acid agent (SOURS) | 1.5 | 2.0 |
10 | Acid agent (SOURS) | 1.5 | 2.0 |
11 | Acid agent (SOURS) | 1.5 | 2.0 |
12 | Acid agent (SOURS) | 1.5 | 2.0 |
13 | Acid agent (SOURS) | 1.5 | 2.0 |
14 | Acid agent (SOURS) | 1.5 | 2.0 |
Embodiment | The kind of film | Silicon dioxide 1(weight %) | Magnesium stearate (weight %) |
15 | Benzocaine/menthol | 1.5 | 1.5 |
16 | Benzocaine/menthol | 1.5 | 1.5 |
17 | Benzocaine/menthol | 1.5 | 1.5 |
18 | Benzocaine/menthol | 1.5 | 1.5 |
19 | Benzocaine/menthol | 1.5 | 1.5 |
20 | Acid agent (SOURS) | 2 | 2.5 |
21 | Acid agent (SOURS) | 1.5 | 2 |
22 | Acid agent (SOURS) | 1.5 | 2 |
23 | Acid agent (SOURS) | 1.5 | 2 |
24 | Acid agent (SOURS) | 1.5 | 2 |
25 | Acid agent (SOURS) | 1.5 | 2 |
26 | Acid agent (SOURS) | 1.5 | 2 |
27 | Acid agent (SOURS) | 1.5 | 2.5 |
28 | Acid agent (SOURS) | 1.5 | 2.5 |
29 | Acid agent (SOURS) | 1.5 | 2.5 |
30 | Acid agent (SOURS) | 1.5 | 2.5 |
31 | Acid agent (SOURS) | 1.5 | 2 |
32 | Acid agent (SOURS) | 1.5 | 2 |
33 | Acid agent (SOURS) | 1.5 | 2.5 |
34 | Acid agent (SOURS) | 1.5 | 2.5 |
35 | Acid agent (SOURS) | 1.5 | 2.5 |
36 | Acid agent (SOURS) | 1.5 | 2.5 |
37 | Acid agent (SOURS) | 1.5 | 2.5 |
38 | Acid agent (SOURS) | 1.5 | 2.5 |
39 | Acid agent (SOURS) | 1.5 | 2.5 |
40 | Acid agent (SOURS) | 1.5 | 2.5 |
41 | Energy/healthy supplement 2 | 1 | 2 |
42 | Energy/healthy supplement 2 | 1 | 2 |
43 | Energy/healthy supplement 2 | 0.9 | 1 |
44 | Energy/healthy supplement 2 | 1.15 | 1 |
45 | Energy/healthy supplement 2 | 1 | 1 |
46 | Energy/healthy supplement 2 | 0.75 | 1 |
47 | Energy/healthy supplement 2 | 1 | 1.5 |
48 | Energy/healthy supplement 2 | 1 | 1 |
49 | Energy/healthy supplement 2 | 0.75 | 1 |
50 | Energy/healthy supplement 2 | 1 | 1 |
51 | Energy/healthy supplement 2 | 1 | 1 |
52 | Energy/healthy supplement 2 | 1 | 1 |
53 | Energy/healthy supplement 2 | 1 | 1 |
Embodiment | The kind of film | Silicon dioxide 1(weight %) | Magnesium stearate (weight %) |
54 | Energy/healthy supplement 2 | 1 | 1 |
55 | Energy/healthy supplement 2 | 1 | 1 |
56 | Energy/healthy supplement 2 | 1 | 1 |
57 | Energy/healthy supplement 2 | 1 | 1 |
58 | Energy/healthy supplement 2 | 1 | 1 |
59 | Energy/healthy supplement 2 | 1 | 1 |
60 | Energy/healthy supplement 2 | 1 | 1 |
61 | Energy/healthy supplement 2 | 1 | 1.5 |
62 | Energy/healthy supplement 2 | 0.5 | 1.5 |
63 | The oral pain alleviating agent | 0.54 | 0.5 |
64 | The oral pain alleviating agent | 1.54 | 1 |
65 | The oral pain alleviating agent | 0.5 | 0.54 |
66 | The oral pain alleviating agent | 1.54 | 1 |
67 | The oral pain alleviating agent | 1.04 | 1 |
68 | The oral pain alleviating agent | 1.24 | 1.5 |
69 | The oral pain alleviating agent | 1.24 | 1.5 |
70 | The oral pain alleviating agent | 1.24 | 1.5 |
71 | The oral pain alleviating agent | 1.24 | 1.5 |
72 | The oral pain alleviating agent | 1.24 | 1.5 |
73 | The oral pain alleviating agent | 1.24 | 1.5 |
74 | Energy/healthy supplement 2 | 0.5 | 1.5 |
75 | Melatonin | 1 | 2 |
76 | Melatonin | 1 | 2 |
77 | Melatonin | 1 | 2 |
78 | Melatonin | 1 | 1.5 |
79 | Melatonin | 1.1 | 1.3 |
80 | Melatonin | 1.2 | 1.3 |
81 | Chlorine dioxide | 1.5 | 1.5 |
82 | Multivitamin | 1 | 1 |
83 | Multivitamin | 1 | 1 |
84 | Zinc/Ramulus Sambuci Williamsii | 0.5 | 1 |
85 | Energy/healthy supplement 2 | 0.75 | 1 |
86 | Energy/healthy supplement 2 | 0.75 | 1 |
87 | Energy/healthy supplement 2 | 0.75 | 1 |
88 | Melatonin | 1.1 | 1.3 |
89 | Multivitamin | 1 | 1 |
90 | Compound vitamin B | 1 | 1 |
91 | Multivitamin | 1 | 1 |
92 | Compound vitamin B | 1 | 1 |
Embodiment | The kind of film | Silicon dioxide 1(weight %) | Magnesium stearate (weight %) |
93 | Multivitamin | 1 | 1 |
94 | Multivitamin | 1 | 1 |
95 | Energy/healthy supplement 2 | 0.75 | 1 |
96 | Multivitamin | 1 | 1 |
97 | Melatonin | 1 | 1 |
98 | Energy/healthy supplement 2 | 0.75 | 1 |
99 | Energy/healthy supplement 2 | 0.75 | 1 |
100 | Energy/healthy supplement 2 | 0.75 | 1 |
101 | Energy/healthy supplement 2 | 1 | 1.5 |
102 | Energy/healthy supplement 2 | 1 | 1.5 |
103 | Energy/healthy supplement 2 | 1 | 2 |
104 | Energy/healthy supplement 2 | 1.5 | 1 |
105 | Energy/healthy supplement 2 | 1 | 2 |
106 | Energy/healthy supplement 2 | 1 | 2 |
107 | Energy/healthy supplement 2 | 1 | 1.5 |
108 | Energy/healthy supplement 2 | 1 | 2 |
109 | Energy/healthy supplement 2 | 1 | 1.5 |
110 | Energy/healthy supplement 2 | 1 | 1.5 |
111 | Energy/healthy supplement 2 | 1 | 1.5 |
112 | Energy/healthy supplement 2 | 1 | 1.5 |
113 | Energy/healthy supplement 2 | 1 | 1.5 |
114 | Energy/healthy supplement 2 | 1 | 1.5 |
115 | Multivitamin | 1 | 1.5 |
116 | Multivitamin | 1 | 1.5 |
117 | Immunostimulant | 1 | 1 |
118 | Melatonin | 1.1 | 1.3 |
119 | Melatonin | 1.1 | 1.3 |
120 | Melatonin | 1.1 | 1.3 |
121 | Melatonin | 1.1 | 1.3 |
122 | Melatonin | 0.5 | 0.75 |
123 | Flu and cough medicine (COLD﹠COUGH) | 1 | 1 |
124 | Flu and cough medicine (COLD﹠COUGH) | 1 | 1 |
125 | Multivitamin | 1 | 1 |
126 | Multivitamin | 1 | 1 |
127 | Multivitamin | 1 | 1.5 |
128 | Multivitamin | 1 | 1 |
129 | Multivitamin | 1 | 1 |
130 | Multivitamin | 1 | 1.5 |
131 | Multivitamin | 1 | 1 |
Embodiment | The kind of film | Silicon dioxide 1(weight %) | Magnesium stearate (weight %) |
132 | Multivitamin | 1 | 1 |
133 | Compound vitamin B | 1 | 1 |
134 | Compound vitamin B | 1 | 1 |
135 | Compound vitamin B | 1 | 1 |
136 | Compound vitamin B | 1 | 1 |
137 | Energy/healthy supplement 2 | 1.5 | 1.5 |
138 | Energy/healthy supplement 2 | 1.5 | 1.5 |
139 | Energy/healthy supplement 2 | 1.5 | 1.5 |
140 | Multivitamin | 1 | 1 |
141 | Compound vitamin B | 1 | 1 |
142 | Compound vitamin B | 1 | 1 |
143 | Multivitamin | 1 | 1 |
144 | Compound vitamin B | 1 | 1 |
145 | Multivitamin | 1 | 1 |
146 | Multivitamin | 1 | 1 |
147 | Multivitamin | 1 | 1 |
148 | Multivitamin | 1 | 1 |
149 | Compound vitamin B | 1 | 1 |
150 | Compound vitamin B | 1 | 1 |
151 | Multivitamin | 1 | 1 |
152 | Multivitamin | 1 | 1 |
153 | Multivitamin | 1 | 1 |
154 | Multivitamin | 1.5 | 0.3 |
155 | Energy/healthy supplement 2 | 1.5 | 1 |
156 | Energy/healthy supplement 2 | 1 | 1 |
157 | Energy/healthy supplement 2 | 1 | 1 |
158 | Multivitamin | 1 | 1 |
159 | Multivitamin | 1 | 1 |
160 | Multivitamin | 1.5 | 0.3 |
161 | Multivitamin | 1 | 1 |
162 | Compound vitamin B | 1 | 1 |
163 | Compound vitamin B | 1 | 1 |
164 | Energy/healthy supplement 2 | 0.5 | 0.5 |
165 | Energy/healthy supplement 2 | 0.5 | 0.5 |
166 | Energy/healthy supplement 2 | 0.5 | 0.5 |
167 | Energy/healthy supplement 2 | 0.5 | 0.5 |
168 | Energy/healthy supplement 2 | 0.5 | 0.5 |
169 | Energy/healthy supplement 2 | 0.5 | 0.5 |
170 | Energy/healthy supplement 2 | 0.5 | 0.5 |
Embodiment | The kind of film | Silicon dioxide 1(weight %) | Magnesium stearate (weight %) |
171 | Energy/healthy supplement 2 | 1 | 0.5 |
172 | Energy/healthy supplement 2 | 1 | 0.5 |
173 | Multivitamin | 1 | 1 |
174 | Multivitamin | 1 | 1 |
175 | Energy/healthy supplement 2 | 0.5 | 0.5 |
176 | Multivitamin | 1 | 1 |
177 | Energy/healthy supplement 2 | 0.5 | 0.5 |
178 | Energy/healthy supplement 2 | 0.5 | 0.5 |
179 | Multivitamin | 1 | 1 |
180 | Multivitamin | 1 | 1 |
181 | Energy/healthy supplement 2 | 1 | 0.5 |
182 | Energy/healthy supplement 2 | 1 | 0.5 |
183 | Multivitamin | 1 | 1 |
184 | Multivitamin | 1 | 1 |
185 | Multivitamin | 1 | 1 |
186 | Multivitamin | 1 | 1 |
187 | Multivitamin | 1 | 1 |
188 | Energy/healthy supplement 2 | 1 | 0.5 |
189 | Multivitamin | 1 | 1 |
190 | Multivitamin | 1 | 1 |
191 | Multivitamin | 1 | 1 |
192 | Multivitamin | 1 | 1 |
193 | Multivitamin | 1.37 | 2.05 |
194 | Multivitamin | 1 | 1 |
195 | Multivitamin | 1 | 1 |
196 | Multivitamin | 1 | 1 |
197 | Compound vitamin B | 1 | 1 |
198 | Energy/healthy supplement 2 | 1 | 0.5 |
199 | Energy/healthy supplement 2 | 1 | 0.5 |
200 | Energy/healthy supplement 2 | 1 | 0.5 |
201 | Compound vitamin B | 1 | 1 |
202 | Multivitamin | 1 | 1 |
203 | Multivitamin | 1 | 1 |
204 | Melatonin | 1.1 | 1.3 |
205 | Multivitamin | 1.5 | 0.3 |
206 | Multivitamin | 1 | 1 |
207 | The stress reduction agent | 1 | 0.3 |
208 | Multivitamin | 1 | 1 |
209 | Multivitamin | 1 | 1 |
Embodiment | The kind of film | Silicon dioxide 1(weight %) | Magnesium stearate (weight %) |
210 | Multivitamin | 1 | 1 |
211 | Energy/healthy supplement 2 | 1 | 0.5 |
212 | Energy/healthy supplement 2 | 1 | 0.5 |
213 | Energy/healthy supplement 2 | 1 | 0.5 |
214 | Energy/healthy supplement 2 | 1 | 0.5 |
215 | Energy/healthy supplement 2 | 1 | 0.5 |
216 | Multivitamin | 1.5 | 0.3 |
217 | Melatonin | 1 | 0.5 |
218 | Melatonin | 1 | 0.5 |
219 | The stress reduction agent | 1 | 0.3 |
220 | Multivitamin | 1 | 1 |
221 | Melatonin | 1 | 0.5 |
222 | Multivitamin | 1.5 | 0.3 |
223 | Multivitamin | 1 | 1 |
224 | Multivitamin | 1 | 1 |
225 | Cinnamnt | 1 | 1 |
226 | Melatonin | 1 | 0.5 |
227 | Melatonin | 1 | 0.5 |
228 | Compound vitamin B | 1 | 1 |
229 | Multivitamin | 1 | 1 |
230 | Multivitamin | 1 | 1 |
231 | Multivitamin | 1 | 1 |
232 | Multivitamin | 1 | 1 |
233 | Multivitamin | 1 | 1 |
234 | Multivitamin | 1 | 1 |
235 | Multivitamin | 1 | 1 |
236 | Multivitamin | 1 | 1 |
237 | Multivitamin | 1 | 1 |
238 | Multivitamin | 1 | 1 |
239 | Multivitamin | 1 | 1 |
240 | Multivitamin | 1 | 1 |
241 | Benzocaine/menthol | 1.5 | 1.5 |
242 | Multivitamin | 1 | 1 |
243 | Dextromethorphan hydrobromide | 0.5 | 1.82 |
1Sipernat 500LS available from Degussa (Degussa)
2Any/all following activating agents or its combination that energy/healthy supplement can contain:
Green tea, brazilian cocoa, methylpyrrole chromium, caffeine, Yohimbine Hcl, taurine, vitamin B3, vitamin B6, vitamin B12
Except silicon dioxide and magnesium stearate, also contain various components such as polymer and flavoring agent etc. in every kind of film listing above.All the other components of the every kind of film that adopts in the table 2 are as described below.
The film that is defined as " sour agent " in the last table 2 contains the following component listed as table 3:
Table 3
Component | Weight % |
Hydroxypropyl emthylcellulose | 0.01%-60% |
Citric acid | 0.01%-40% |
Natural and synthetic flavoring agent | 0.01%-25% |
Arabic gum | 0.01%-10% |
Magnesium stearate | 0.01%-10% |
Sodium hexameta phosphate | 0.01%-5% |
Silicon dioxide | 0.01%-2% |
Polyoxyethylene sorbitan monoleate | 0%-5% |
Malic acid | 0.01%-10% |
Aspartame | 0.01%-3.5% |
Acesulfame potassium | 0.01%-0.5% |
Dyestuff | 0.01%-1% |
Potassium sorbate | 0.01%-0.1% |
Sodium benzoate | 0.01%-0.1% |
The film that is defined as " benzocaine/menthol " in the last table 2 contains the following component listed as table 4:
Table 4
Component | Weight % |
Hydroxypropyl emthylcellulose | 0.01%-70% |
Natural and synthetic flavoring agent | 0.01%-25% |
Poly(ethylene oxide) | 0.01%-50% |
The menthol crystal | 0.01%-30% |
Corn starch | 0.01%-30% |
Benzocaine | 0.01%-10% |
Sucralose | 0.01%-5% |
Malic acid | 0.01%-5% |
Magnesium stearate | 0.01%-10% |
Silicon dioxide | 0.01%-2% |
Titanium dioxide | 0.01%-5% |
Butylated hydroxy-methylbenzene | 0.01%-1% |
Dyestuff | 0.01%-1% |
The film that is defined as " energy/healthy supplement " in the last table 2 contains the following component listed as table 5:
Table 5
Component | Weight % |
Hydroxypropyl emthylcellulose | 0%-70%% |
Hydroxypropyl cellulose | 0%-40% |
Pectin | 0%-40% |
Natural and synthetic flavoring agent/seasoning adjuvant | 0%-30% |
Dextrosan | 0.01%-30% |
Sodium carboxymethyl cellulose | 0%-10% |
Energy/healthy activating agent 2 | 0.01%-50% |
Erithritol | 0%-20% |
Sucralose | 0.01%-5% |
Citric acid | 0%-10% |
Magnesium stearate | 0.01%-10% |
Glyceryl monooleate | 0%-1% |
Silicon dioxide | 0.01%-2% |
Polyoxyethylene sorbitan monoleate | 0%-1% |
The sorbitan monoleate | 0%-1% |
Potassium sorbate | 0%-0.1% |
Sodium benzoate | 0%-0.1% |
Sodium hexameta phosphate | 0%-10% |
Propylene glycol | 0%-25% |
Arabic gum | 0%-10% |
Dyestuff | 0.01%-1% |
The film that is defined as " oral pain alleviating agent " in the last table 2 contains the following component listed as table 6:
Table 6
Component | Weight % |
Hydroxypropyl emthylcellulose | 0.01%-70% |
Choline salicylate | 0.01%-60% |
Natural and synthetic flavoring agent | 0.01%-10% |
Magnesium stearate | 0.01-5% |
Silicon dioxide | 0.01-2% |
Cetalkonium chloride | 0.01%-5% |
Methyl parahydroxybenzoate | 0.01%-0.1% |
Dimethyl polysiloxane | 0.01%-0.05% |
The film that is defined as " melatonin " in the last table 2 contains the following component listed as table 7:
Table 7
Component | Weight % |
Hydroxypropyl emthylcellulose | 0.01%-70% |
Natural and synthetic flavoring agent/seasoning adjuvant | 0.01%-20% |
Poly(ethylene oxide) | 0.01%-30% |
Melatonin | 0.01%-20% |
Pectin | 0.01%-10% |
Dextrosan | 0.01%-20% |
Sucralose | 0.01%-5% |
Magnesium stearate | 0.01%-10% |
Silicon dioxide | 0.01%-2% |
Glyceryl monooleate | 0.01%-1% |
Titanium dioxide | 0.01%-5% |
Monoammonium glycyrrhizinate | 0.01%-2% |
Butylated hydroxy-methylbenzene | 0.01%-1% |
Dyestuff | 0.01%-1% |
The film that is defined as " chlorine dioxide " in the last table 2 contains the following component listed as table 8:
Table 8
Component | Weight % |
Hydroxypropyl emthylcellulose | 0.01%-70% |
Poly(ethylene oxide) | 0.01%-50% |
Dextrosan | 0.01%-20% |
Natural and synthetic flavoring agent/seasoning adjuvant | 0.01%-30% |
Magnesium stearate | 0.01%-5% |
Silicon dioxide | 0.01%-2% |
Sucralose | 0.01%-5% |
The zinc gluconate dihydrate | 0.01%-5% |
Citric acid | 0.01%-2% |
Glyceryl monooleate | 0.01%-1% |
Sodium hydroxide | 0.01%-5% |
Sodium bicarbonate | 0.01%-5% |
2% ClO 2 solution | 0.01%-10% |
Butylated hydroxy-methylbenzene | 0.01%-1% |
Dyestuff | 0.01%-1% |
Sodium benzoate | 0.01%-0.1% |
The film that is defined as " multivitamin " in the last table 2 contains the following component listed as table 9:
Table 9
Component | Weight % |
Hydroxypropyl emthylcellulose | 0.01%-50% |
Natural and synthetic flavoring agent | 0.01%-20% |
Nicotiamide-100% (vitamin B3) | 0.01%-30% |
Poly(ethylene oxide) | 0.01%-30% |
Dextrosan | 0.01%-20% |
Ascorbic acid-100% (vitamin C) | 0.01%-20% |
50% alpha-tocopherol acetate-91.2% | 0.01%-10% |
Dextro calcium pantothenate-92% (vitamin B5) | 0.01%-10% |
Sucralose | 0.01%-5% |
Palimitate-A-15% | 0.01%-10% |
Hydrochloric acid pyrrole-82.3% (vitamin B6) of trembling | 0.01%-10% |
Riboflavin-100% (vitamin B2) | 0.01%-10% |
Thiamine hydrochloride-89.2% (vitamin B 1) | 0.01%-10% |
Magnesium stearate | 0.01%-2% |
Silicon dioxide | 0.01%-2% |
Glyceryl monooleate | 0.01%-1% |
5% phytomenadione 00% | 0.01%-5% |
2.5% vitamin D3 liquid-100% | 0.01%-5% |
Butylated hydroxy-methylbenzene | 0.01%-1% |
Cyanogen cobalt vitamin-100% (vitamin B12) | 0.001%-1% |
The film that is defined as " zinc/Ramulus Sambuci Williamsii " in the last table 2 contains the following component listed as table 10:
Table 10
Component | Weight % |
Hydroxypropyl emthylcellulose | 0.01%-60% |
Zinc gluconate | 0.01%-20% |
The fruit of Ramulus Sambuci Williamsii extract | 0.01%-20% |
Fructose | 0.01%-20% |
Natural and synthetic flavoring agent | 0.01%-30% |
Poly(ethylene oxide) | 0.01%-20% |
Dextrosan | 0.01%-20% |
Ascorbic acid-100% (vitamin C) | 0.01%-20% |
Sucralose | 0.01%-5% |
Glyceryl monooleate | 0.01%-1% |
Magnesium stearate | 0.01%-5% |
Titanium dioxide | 0.01%-2% |
Silicon dioxide | 0.01%-2% |
Butylated hydroxy-methylbenzene | 0.01%-1% |
The film that is defined as " compound vitamin B " in the last table 2 contains the following component listed as table 11:
Table 11
Component | Weight % |
Hydroxypropyl emthylcellulose | 0.01%-60% |
Poly(ethylene oxide) | 0.01%-50% |
Dextro calcium pantothenate-92% (vitamin B5) | 0.01%-20% |
Dextrosan | 0.01%-30% |
Natural and synthetic flavoring agent/seasoning adjuvant | 0.01%-25% |
Hydrochloric acid pyrrole-82.3% (vitamin B6) of trembling | 0.01%-20% |
Riboflavin-100% (vitamin B2) | 0.01%-20% |
Thiamine hydrochloride-89.2% (vitamin B1) | 0.01%-20% |
Sucralose | 0.01%-5% |
Propylene glycol | 0.01%-5% |
Magnesium stearate | 0.01%-10% |
Silicon dioxide | 0.01%-2% |
Glyceryl monooleate | 0.01%-1% |
Butylated hydroxy-methylbenzene | 0.01%-1% |
Dyestuff | 0.01%-1% |
Cyanogen cobalt vitamin-100% (vitamin B12) | 0.001%-1% |
The film that is defined as " immunostimulant " in the last table 2 contains the following component listed as table 12:
Table 12
Component | Weight % |
Hydroxypropyl emthylcellulose | 0.01%-70% |
Dextrosan | 0.01%-50% |
Poly(ethylene oxide) | 0.01%-50% |
Zinc citrate trihydrate. | 0.01%-40% |
Sucralose | 0.01%-5% |
Natural flavouring | 0.01%-20% |
Citric acid | 0.01%-20% |
Magnesium stearate | 0.01%-10% |
Silicon dioxide | 0.01%-2% |
Sodium citrate | 0.01%-5% |
Glyceryl monooleate | 0.01%-1% |
Butylated hydroxy-methylbenzene | 0.01%-2% |
Monoammonium glycyrrhizinate | 0.01%-1% |
Dyestuff | 0.01%-1% |
The film that is defined as " flu and cough medicine " in the last table 2 contains the following component listed as table 13:
Table 13
Component | Weight % |
Hydroxypropyl emthylcellulose | 0.01%-60% |
Dextrosan | 0.01%-30% |
Natural and synthetic flavoring agent | 0.01%-25% |
Poly(ethylene oxide) | 0.01%-50% |
Ascorbic acid-100% (vitamin C) | 0.01%-30% |
The zinc citrate dihydrate | 0.01%-20% |
Echinacea extract (ECHINACEA PURPUREA) | 0.01%-20% |
Sucralose | 0.01%-10% |
Pectin | 0.01%-20% |
Citric acid | 0.01%-10% |
Sodium citrate | 0.01%-5% |
Magnesium stearate | 0.01%-10% |
Silicon dioxide | 0.01%-2% |
Glyceryl monooleate | 0.01%-1% |
Dyestuff | 0.01%-1% |
Butylated hydroxy-methylbenzene | 0.01%-1% |
Monoammonium glycyrrhizinate | 0.01%-1% |
The film that is defined as " stress reduction agent " in the last table 2 contains the following component listed as table 14:
Table 14
Component | Weight % |
Hydroxypropyl emthylcellulose | 0.01%-60% |
Flos Chrysanthemi | 0.01%-40% |
Herba Passiflorae Caeruleae | 0.01%-40% |
Pectin | 0.01%-20% |
Natural and synthetic flavoring agent | 0.01%-25% |
Glycerol | 0.01%-10% |
Polyoxyethylene sorbitan monoleate | 0%-2% |
Sucralose | 0.01%-5% |
Polydimethylsiloxane Emulsion | 0.01%-2% |
Aspartame | 0.01%-5% |
Acesulfame potassium | 0.01%-3% |
Potassium sorbate | 0.01%-1% |
The film that is defined as " cinnamnt " in the last table 2 contains the following component listed as table 15:
Table 15
Form | Weight % |
Hydroxypropyl emthylcellulose | 0.01%-70% |
Poly(ethylene oxide) | 0.01%-50% |
Dextrosan | 0.01%-30% |
Butylated hydroxy-methylbenzene | 0.01%-1% |
Glyceryl monooleate | 0.01%-1% |
Magnesium stearate | 0.01%-10% |
Silicon dioxide | 0.01%-2% |
Potassium sorbate | 0.01%-0.1% |
Sodium benzoate | 0.01%-0.1% |
Natural and synthetic flavoring agent | 0.01%-30% |
Sucralose | 0.01%-5% |
Xylitol | 0.01%-10% |
Dyestuff | 0.01%-1% |
The film that is defined as " dextromethorphan hydrobromide " in the last table 2 contains the following component listed as table 16:
Table 16
Component | Weight % |
Dextromethorphan hydrobromide 60% | 0.01%-60% |
Poly(ethylene oxide) | 0.01%-70% |
Dextrosan | 0.01%-30% |
Hydroxypropyl emthylcellulose | 0.01%-70% |
Natural and synthetic flavoring agent | 0.01%-30% |
Sucralose | 0.01%-5% |
Magnesium stearate | 0.01%-10% |
Silicon dioxide | 0%-2% |
Sodium bicarbonate | 0.01%-5% |
Xanthan gum | 0.01%-10% |
Titanium dioxide | 0.01%-5% |
Butylated hydroxy-methylbenzene | 0.01%-1% |
Dyestuff | 0.01%-1% |
The film for preparing among these embodiment has the fluidizer characteristic of improvement, especially has the ability of adhesion ground slip to each other.
Embodiment 244-300:
Be combined with as the silicon dioxide of antiplastering aid and the water-soluble film of magnesium stearate with the described content preparation of table 17.More specifically say, as shown in the table, various silicon dioxide and magnesium stearate combination are mixed in the various film composition.
Table 17
Embodiment | The kind of film | Silicon dioxide 1(weight %) | Magnesium stearate (weight %) |
244 | Acid agent (SOURS) | 1.5 | 2.5 |
245 | Energy/healthy supplement 2 | 0.75 | 1 |
246 | Energy/healthy supplement 2 | 0.75 | 1 |
247 | Melatonin | 1 | 2 |
248 | Melatonin | 1.5 | 1.5 |
249 | Chlorine dioxide | 1.5 | 1.5 |
250 | Melatonin | 1.5 | 1.5 |
251 | Melatonin | 1.5 | 1.5 |
252 | Melatonin | 1.5 | 1.5 |
253 | Melatonin | 1.5 | 1.5 |
254 | Chlorine dioxide | 1.5 | 1.5 |
255 | Melatonin | 1.1 | 1.3 |
256 | Multivitamin | 1 | 1 |
257 | Multivitamin | 1 | 1 |
258 | Compound vitamin B | 1 | 1 |
259 | Multivitamin | 1 | 1 |
260 | Compound vitamin B | 1 | 1 |
Embodiment | The kind of film | Silicon dioxide 1(weight %) | Magnesium stearate (weight %) |
261 | Flu and cough medicine (COLD﹠COUGH) | 1 | 1 |
262 | Multivitamin | 1 | 1 |
263 | Multivitamin | 1 | 1 |
264 | Multivitamin | 1 | 1 |
265 | Multivitamin | ||
266 | Multivitamin | ||
267 | Multivitamin | ||
268 | Multivitamin | 1 | 1.5 |
269 | Immunostimulant | 1.16 | 1.16 |
270 | Multivitamin | 1 | 1 |
271 | Energy/healthy supplement 2 | 1 | 1.5 |
272 | Multivitamin | 1 | 1.5 |
273 | Multivitamin | 1 | 1.5 |
274 | Melatonin | 1.1 | 1.3 |
275 | Multivitamin | 1 | 1 |
276 | Multivitamin | 1 | 1 |
277 | Multivitamin | 1 | 1 |
278 | Multivitamin | 1 | 1 |
279 | Multivitamin | 1 | 1 |
280 | Energy/healthy supplement 2 | 1.5 | 1.5 |
281 | Multivitamin | 1 | 1.5 |
282 | Multivitamin | 1 | 1.5 |
283 | Multivitamin | 1.5 | 0.3 |
284 | Multivitamin | 1 | 1 |
285 | Compound vitamin B | 1 | 1 |
286 | Energy/healthy supplement 2 | 1 | 0.5 |
287 | Multivitamin | 1 | 1 |
288 | Melatonin | 1.1 | 1.3 |
289 | Compound vitamin B | 1 | 1 |
290 | Compound vitamin B | 1 | 1 |
291 | Energy/healthy supplement 2 | 1 | 0.5 |
292 | Energy/healthy supplement 2 | 1 | 0.5 |
293 | Compound vitamin B | 1 | 1 |
294 | Multivitamin | 1 | 1 |
295 | Chlorine dioxide | 1.5 | 1.5 |
296 | Multivitamin | 1 | 1.5 |
297 | Multivitamin | 1 | 1 |
298 | Multivitamin | 1 | 1 |
Embodiment | The kind of film | Silicon dioxide 1(weight %) | Magnesium stearate (weight %) |
299 | Multivitamin | 1 | 1 |
300 | Benzocaine/menthol | 1.5 | 1.5 |
1Sipernat 500LS available from Degussa (Degussa)
2Any/all following activating agents or its combination that energy/healthy supplement can contain:
Green tea, brazilian cocoa, methylpyrrole chromium, caffeine, Yohimbine Hcl, taurine, vitamin B3, vitamin B6, vitamin B12 are except silicon dioxide and magnesium stearate, and be relevant with last table 2 as contained all the other components in the listed film of table 17.
Table 2 is identical with the kind of 17 films that adopt.
The film for preparing among these embodiment has the fluidizer characteristic of improvement, especially has the ability of adhesion ground slip to each other.
Think the preferred embodiment of the present invention at present although described, but those skilled in the art will recognize that, can make a change and modify it when not deviating from the present invention's spirit, the present invention be intended to comprise that all these classes change and modification, and it is fallen within the true scope of the present invention.
Claims (26)
1. edible film that is used for active agent delivery comprises:
The edible water-soluble polymer;
At least a antiplastering aid, it is selected from lubricant, antitack agent, fluidizer and combination thereof; With
Active component, it is selected from enamel, medicament, vitamin, bioactivator and combination thereof,
Wherein said film is a self-supporting.
2. film as claimed in claim 1 is characterized in that described antiplastering aid comprises vitamin E TPGS.
3. film as claimed in claim 1 is characterized in that described antiplastering aid comprises magnesium stearate.
4. film as claimed in claim 3 is characterized in that described antiplastering aid also comprises silicon dioxide.
5. film as claimed in claim 1 is characterized in that the content of described antiplastering aid accounts for the 0.01-20% of described delivery system weight.
6. film as claimed in claim 1 is characterized in that, described antiplastering aid comprises:
Content accounts for the magnesium stearate of the 0.1-2.5% of described delivery system weight; With
Content accounts for the silicon dioxide of the 0.1-1.5% of described delivery system weight.
7. film as claimed in claim 1 is characterized in that described water-soluble polymer comprises poly(ethylene oxide) and cellulosic polymer.
8. film as claimed in claim 7 is characterized in that described cellulosic polymer comprises hydroxypropyl cellulose.
9. film as claimed in claim 7 is characterized in that described cellulosic polymer comprises hydroxypropyl emthylcellulose.
10. film as claimed in claim 1 is characterized in that described active component comprises dextromethorphan.
11. film as claimed in claim 1 is characterized in that, also comprises dextrosan.
12. film as claimed in claim 1 is characterized in that, described film is used for mammiferous oral cavity.
13. film as claimed in claim 13 is characterized in that, described film adheres to mammiferous tongue.
14. the edible film of an active agent delivery comprises:
The edible water-soluble polymers compositions, it contains at least a hydroxypropyl cellulose, hydroxypropyl emthylcellulose, poly(ethylene oxide) and the combination of polymers thereof of being selected from;
Active component, it is selected from enamel, medicament, vitamin, bioactivator and combination thereof; With
Antiplastering aid, it contains the vitamin E TPGS that content accounts for described film weight 0.01-20%.
15. an edible film that is used for active agent delivery comprises:
The edible water-soluble polymers compositions, it contains poly(ethylene oxide) and is selected from hydroxypropyl cellulose, hydroxypropyl emthylcellulose and combination of polymers thereof; With
Vitamin E TPGS, its content are enough to provide resistance to bond and treatment characteristic,
Wherein said film is a self-supporting.
16. an edible film that is used for active agent delivery comprises:
The edible water-soluble polymer, it contains poly(ethylene oxide) and hydroxypropyl cellulose;
Dextrosan, the ratio of wherein said poly(ethylene oxide), hydroxypropyl cellulose and dextrosan is about 45: 45: 10;
Active component, it is selected from enamel, medicament, vitamin, bioactivator and combination thereof; With
At least a antiplastering aid.
17. an edible film that is used for active agent delivery comprises:
(a) self-supporting film, it has at least one surface, and described film comprises:
(i) edible water-soluble polymer; With
(ii) active component, it is selected from enamel, medicament, vitamin, bioactivator and combination thereof; With
(b) coating, it covers at least one surface of described self-supporting film, and described coating contains at least a antiplastering aid.
18. a multilayer film that is used for active agent delivery comprises:
(a) at least a first rete, it comprises:
(i) edible water-soluble polymer; With
(ii) antiplastering aid; With
(b) second rete, it comprises:
(i) edible water-soluble polymer; With
(ii) active component, it is selected from enamel, medicament, vitamin, bioactivator and combination thereof,
Wherein said first rete contacts with described second rete basically.
19. multilayer film as claimed in claim 18 is characterized in that, described first rete is laminated on described second rete.
20. one kind prepares and has the method for the self-supporting film of equally distributed component basically, comprising:
(a) with the edible water-soluble polymer, solvent, the active component and at least a antiplastering aid that are selected from enamel, medicament, vitamin, bioactivator and combination thereof mix, and form the substrate that is evenly distributed with described component;
(b) form the self-supporting film by described substrate;
(c) provide surface with end face and bottom surface;
(d) described film is transported on the described end face on described surface; With
(e) the described bottom surface heating to described surface makes the film drying.
21. method as claimed in claim 20 is characterized in that, described antiplastering aid comprises vitamin E TPGS.
22. method as claimed in claim 20 is characterized in that, described antiplastering aid comprises magnesium stearate and silicon dioxide.
23. method as claimed in claim 20 is characterized in that, described substrate also contains dextrosan.
24. method as claimed in claim 20 is characterized in that, described film can absorb.
25. method as claimed in claim 20 is characterized in that, and is flexible when described film is dry.
26. method as claimed in claim 20 is characterized in that, described step (e) comprises that the described bottom surface to described surface applies thermal current, and does not apply the end face air-flow basically.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71552805P | 2005-09-09 | 2005-09-09 | |
US60/715,528 | 2005-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101316579A true CN101316579A (en) | 2008-12-03 |
Family
ID=37808107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800392162A Pending CN101316579A (en) | 2005-09-09 | 2006-09-08 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1931305A2 (en) |
JP (1) | JP2009507854A (en) |
CN (1) | CN101316579A (en) |
AU (1) | AU2006287342A1 (en) |
CA (1) | CA2621263A1 (en) |
WO (1) | WO2007030754A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101928408B (en) * | 2009-06-25 | 2012-01-25 | 中国石油化工股份有限公司 | Composite anti-blocking agent for linear low-density polyethylene film and using method thereof |
CN102753196A (en) * | 2009-12-10 | 2012-10-24 | 莫诺索尔克斯有限公司 | Ph sensitive compounds in taste masking within oral thin film strips |
CN103945834A (en) * | 2011-06-24 | 2014-07-23 | 莫诺索尔克斯有限公司 | Biocompatible film with variable cross-sectional properties |
CN111057162A (en) * | 2019-12-23 | 2020-04-24 | 山东广浦生物科技有限公司 | Modified guar gum and preparation method and application thereof |
CN114053875A (en) * | 2021-11-11 | 2022-02-18 | 自然资源部天津海水淡化与综合利用研究所 | Polyamide composite reverse osmosis membrane with biological pollution resistance and preparation method thereof |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2957281A1 (en) | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Polymer release system |
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
US8663687B2 (en) * | 2001-10-12 | 2014-03-04 | Monosol Rx, Llc | Film compositions for delivery of actives |
WO2004084868A1 (en) | 2003-03-26 | 2004-10-07 | Egalet A/S | Morphine controlled release system |
AU2008258596B2 (en) | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
EP2161021B1 (en) * | 2007-06-07 | 2017-03-08 | Sato Pharmaceutical Co. Ltd. | Medicinal film preparation with rapidly dissolving property and flexibility |
WO2009006218A2 (en) * | 2007-06-29 | 2009-01-08 | Union Carbide Chemicals & Plastics Technology Llc | Personal care dissolvable films |
WO2010086989A1 (en) | 2009-01-29 | 2010-08-05 | 日東電工株式会社 | Intraoral film-shaped base and preparation |
NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
EP3434270A1 (en) | 2009-06-12 | 2019-01-30 | Sunovion Pharmaceuticals Inc. | Sublingual apomorphine |
EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
CN102665666A (en) * | 2009-06-30 | 2012-09-12 | 陶氏环球技术有限责任公司 | Sunscreen-containing dissolvable films |
JP5777170B2 (en) | 2009-10-30 | 2015-09-09 | アイエックス バイオファーマ リミテッド | Fast dissolving solid dosage form |
US12186426B2 (en) | 2009-10-30 | 2025-01-07 | Ix Biopharma Ltd. | Solid dosage form |
JP5588688B2 (en) | 2010-01-28 | 2014-09-10 | 日東電工株式会社 | Film-form preparation |
US8577488B2 (en) * | 2010-02-11 | 2013-11-05 | Monosol Rx, Llc | Method and system for optimizing film production and minimizing film scrap |
JP5751868B2 (en) | 2010-03-30 | 2015-07-22 | 日東電工株式会社 | Film-form preparation and method for producing the same |
JP5800527B2 (en) | 2010-03-30 | 2015-10-28 | 日東電工株式会社 | Stabilized pharmaceutical composition, stabilized pharmaceutical composition solution preparation, film-form preparation and method for producing film-form preparation |
TR201906326T4 (en) * | 2010-04-30 | 2019-05-21 | Allovate Llc | Toothpaste for allergic desensitization with oral mucosa. |
WO2012053006A2 (en) | 2010-10-18 | 2012-04-26 | Panacea Biotec Ltd | Improved oral fast dissolving films comprising combination of polymers and method of preparation thereof |
US20120107402A1 (en) * | 2010-10-29 | 2012-05-03 | Monosol Rx, Llc | Process for analyzing and establishing dosage size in an ingestible film |
JP5875246B2 (en) * | 2010-12-10 | 2016-03-02 | 日東電工株式会社 | Sheet-form preparation and method for producing sheet-form preparation |
JP5555148B2 (en) | 2010-12-10 | 2014-07-23 | 日東電工株式会社 | Sheet-form preparation and method for producing sheet-form preparation |
KR102025238B1 (en) | 2010-12-16 | 2019-09-25 | 선오비온 파마슈티컬스 인코포레이티드 | Sublingual Films |
JP5763994B2 (en) | 2011-07-13 | 2015-08-12 | 日東電工株式会社 | Jelly-form preparation and method for producing the jelly-form preparation |
JP5841433B2 (en) | 2012-01-11 | 2016-01-13 | 日東電工株式会社 | Intraoral film-form base and preparation |
FR2990349B1 (en) * | 2012-05-11 | 2014-08-08 | Pf Medicament | FAST DISINTEGRATING MONOLAYER FILM AND ITS USE IN ORAL HYGIENE |
KR20150059167A (en) | 2012-07-06 | 2015-05-29 | 에갈렛 리미티드 | Abuse deterrent pharmaceutical compositions for controlled release |
WO2014123100A1 (en) * | 2013-02-05 | 2014-08-14 | リンテック株式会社 | Patch-type topical anesthetic |
WO2016172095A1 (en) | 2015-04-21 | 2016-10-27 | Cynapsus Therapeutics, Inc. | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
KR101718790B1 (en) * | 2016-04-05 | 2017-03-23 | (주)씨엘팜 | Oral dissolution film manufacturing device |
IL247161A0 (en) | 2016-08-08 | 2016-12-29 | Rubin Yoram | Adhesive films for quick dissolution in managing oral conditions |
KR101831801B1 (en) * | 2016-11-23 | 2018-02-23 | (주)씨엘팜 | Oral dissolution film wrapped pouch |
JP2018197216A (en) * | 2017-05-24 | 2018-12-13 | 株式会社プラスアルファー | Film sheet type nutrient |
JP7287032B2 (en) | 2019-03-20 | 2023-06-06 | 株式会社リコー | SHEET, SHEET LAMINATED PRODUCT, PHARMACEUTICAL, SHEET MANUFACTURING METHOD, AND SHEET LAMINATED MANUFACTURING METHOD |
DE102021106491A1 (en) * | 2021-03-17 | 2022-09-22 | Lts Lohmann Therapie-Systeme Ag. | ROLLED ORAL THIN FILM WITH HIGH LOADING OF ACTIVE INGREDIENTS |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277407B1 (en) * | 1998-11-10 | 2001-08-21 | Frederick S. Marius | Apparatus and method for tablet fabrication |
EP1110546A1 (en) * | 1999-12-23 | 2001-06-27 | Johnson & Johnson Consumer Companies, Inc. | Method of preparing a water soluble film |
AR032556A1 (en) * | 2001-02-08 | 2003-11-12 | Pharmacia Corp | IMMEDIATE ACTION DRUG FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
WO2002074238A2 (en) * | 2001-02-16 | 2002-09-26 | Lavipharm Laboratories Inc. | Water soluble and palatable complexes |
CA2473967C (en) * | 2001-10-12 | 2011-06-14 | Monosolrx Llc | Thin film with non-self-aggregating uniform heterogeneity, process for their production and drug delivery systems made therefrom |
AU2002362772B2 (en) * | 2001-10-12 | 2007-09-06 | Aquestive Therapeutics, Inc. | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
CA2487882A1 (en) * | 2002-05-31 | 2003-12-11 | University Of Mississippi | Transmucosal delivery of cannabinoids |
GB0312419D0 (en) * | 2003-05-30 | 2003-07-02 | Boots Healthcare Int Ltd | Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess |
JP2007502823A (en) * | 2003-08-15 | 2007-02-15 | キューエルティー・ユーエスエイ・インコーポレーテッド | Adhesive and bioerodible transmucosal drug delivery systems |
US20050075432A1 (en) * | 2003-10-07 | 2005-04-07 | Verrall Andrew P. | Acidulent film and method of making same |
-
2006
- 2006-09-08 AU AU2006287342A patent/AU2006287342A1/en not_active Abandoned
- 2006-09-08 EP EP06803266A patent/EP1931305A2/en not_active Withdrawn
- 2006-09-08 CN CNA2006800392162A patent/CN101316579A/en active Pending
- 2006-09-08 JP JP2008530237A patent/JP2009507854A/en active Pending
- 2006-09-08 WO PCT/US2006/035149 patent/WO2007030754A2/en active Application Filing
- 2006-09-08 CA CA002621263A patent/CA2621263A1/en not_active Abandoned
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101928408B (en) * | 2009-06-25 | 2012-01-25 | 中国石油化工股份有限公司 | Composite anti-blocking agent for linear low-density polyethylene film and using method thereof |
CN102753196A (en) * | 2009-12-10 | 2012-10-24 | 莫诺索尔克斯有限公司 | Ph sensitive compounds in taste masking within oral thin film strips |
CN103945834A (en) * | 2011-06-24 | 2014-07-23 | 莫诺索尔克斯有限公司 | Biocompatible film with variable cross-sectional properties |
CN111057162A (en) * | 2019-12-23 | 2020-04-24 | 山东广浦生物科技有限公司 | Modified guar gum and preparation method and application thereof |
CN111057162B (en) * | 2019-12-23 | 2021-09-24 | 山东广浦生物科技有限公司 | Modified guar gum and preparation method and application thereof |
CN114053875A (en) * | 2021-11-11 | 2022-02-18 | 自然资源部天津海水淡化与综合利用研究所 | Polyamide composite reverse osmosis membrane with biological pollution resistance and preparation method thereof |
CN114053875B (en) * | 2021-11-11 | 2022-05-17 | 自然资源部天津海水淡化与综合利用研究所 | Polyamide composite reverse osmosis membrane with biological pollution resistance and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2007030754A2 (en) | 2007-03-15 |
EP1931305A2 (en) | 2008-06-18 |
JP2009507854A (en) | 2009-02-26 |
AU2006287342A1 (en) | 2007-03-15 |
WO2007030754A3 (en) | 2007-05-10 |
CA2621263A1 (en) | 2007-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101316579A (en) | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions | |
CN101534803A (en) | A method of administering a film product containing a drug | |
CN101668519A (en) | Polymer-based films and drug delivery system prepared therefrom | |
US9855221B2 (en) | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions | |
CN101616660A (en) | High dose film compositions and preparation method thereof | |
CN100356908C (en) | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom | |
CN101321511A (en) | Topical film compositions for delivery of actives | |
JP6035369B2 (en) | Thin film with uniform heterogeneity that does not self-aggregate, method for producing the same, and drug delivery system produced therefrom | |
CN101516331A (en) | Edible water-soluble film containing a foam reducing flavoring agent | |
CN105229401B (en) | By controlling loss on drying to make the method for wet film drying | |
CN101889990A (en) | Ondansetron film compositions | |
JP2010509905A6 (en) | Eatable water-soluble film containing flavor enhancer to reduce foaming | |
EP2167034A1 (en) | Film shreds and delivery systems incorporating same | |
CN101346135A (en) | PH modulated films for delivery of actives | |
CN106999601A (en) | Film product based on straight-chain polysaccharide | |
US11077068B2 (en) | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions | |
CN105209026A (en) | Films and drug delivery systems for rizatriptan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20081203 |